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ABSTRACT

Biomimetic and Medical Applications of Hollow Nanoscale Structures
by
Justin Fang

Advisor: Hiroshi Matsui

Materials whose structure incorporates nanoscale void spaces have multiple possible
uses, whether in a bulk form or as individual particles, due to the combination of high surface
area ratios and nanoscale material properties. This thesis will explore a few of these possibilities,
concentrating on potential biomimetic and biomedical applications, for two materials: metalorganic frameworks and superparamagnetic iron oxide nanocages.
Metal-organic frameworks consist of metal ions such as Cu2+ which have highly porous
lattice structures allowing them to absorb and release guest molecules such as peptides like
diphenylalanine; this stored chemical energy can be turned into kinetic energy and used to selfpropel a metal-organic framework particle across an aqueous surface by creating a surface
tension gradient. This motion can in turn be converted into electrical energy or guided to a target
by forming a pH gradient.

iv

Superparamagnetic iron oxide nanocages are hollow nanoparticles which have a
combination of traits such as low toxicity, high surface area to mass ratio, easy chemical
functionalization, and magnetic properties which are potentially useful in a drug delivery system.
In particular, it will be shown that delivery using nanocages increase the chemotherapeutic
effectiveness of a small molecule drug, Riluzole, in both in vitro and in vivo models. It is also the
shown that superparamagnetic properties of nanocages can be used to control the release of
siRNA from the nanocages, resulting in the siRNA targeted suppression of protein expression
occurring only after an alternating magnetic field is applied.
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Chapter 1 Metal-Organic Framework Motors

1.1 Background
Metal-organic frameworks are highly porous materials consisting of metal ions
complexed with organic linker molecules in a lattice structure.1 Their ability to adsorb large
amounts of other molecules has led to a variety of proposed applications such as catalysts or gas
absorbents and seperators.2–5 This research considers another possible application, loading the
matrix with a substituent which generates kinetic energy upon release, essentially acting as a
microscale motor. Many microscale biological systems are capable of converting stored chemical
energy to motion. The ability to imitate these systems with biomimetic motors would have a
variety of potential applications in areas such as microfluidics and microrobotics.6
This motor uses the Marangoni effect: a gradient in surface tension across a liquid surface
causes a fluid flow from areas of lower surface tension to areas of higher surface tension.7 This
flow can be utilized to move particles along the surface. Gradients in surface tension can be
generated in several ways, such as by applying hydrophobic molecules, surfactant molecules, or
local changes in temperature.7–9
A particle which generates a surface tension gradient can thus self-propel using the
Marangoni effect. The classical example of this is the “camphor boat”.10 A small piece of the
waxy solid camphor, when placed on a water surface, slowly releases camphor molecules onto
the surrounding surface. As camphor molecules are hydrophobic, this lowers the surface tension
1

in the immediate area. The surface tension gradient this creates results in the particle moving out
of the immediate area and towards a fresh area of surface, where the process repeats. This
mechanism can be generalized as a model featuring a host particle which releases guest particles
onto an aqueous surface to create a surface tension gradient.
Previously, a system employing the Marangoni effect to propel a particle across an
aqueous surface was demonstrated using the copper MOF CuJAST-1 as the host particle and
diphenylalanine dipeptide (DPA) as the guest.11 (Figure 1) In an aqueous solution containing
EDTA, the copper ions in the CuJAST-1 framework will be slowly chelated away by EDTA,
dissolving the network and releasing the DPA. Due to their hydrophobic nature and π-π stacking
interactions between the aromatic phenyl rings, DPA molecules self-assemble into tubular
structures in an aqueous environment.12 When on the surface of the liquid these structures form
hydrophobic domains that lower the local surface tension, triggering the Marangoni effect.
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Another variation explored here is to use a rotor with a fixed axis, resulting in regular
circular motion of the particle/rotor. A small magnet is then placed on the rotor arm and a wire
coil positioned so that the magnet regularly passes underneath, turning the system into an electric
generator. (Figure 4)
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Figure 1. a) Illustration of DPA peptide–MOF motor design and moving mechanism. DPA peptides are incorporated in pores of HKUST-1 MOF (left).
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Figure 5: a) Solubility of DPA in NaOH/EDTA solutions
of different pH; b)Total duration of MOF/DPA movement
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This behavior can be used to guide Figure
the particle
a particular
if the QDs.
area around
S-2.toTEM
imagetarget
of PbSe
Scalethe
bar = 200 nm. I
diffraction that match with the pattern of PbSe.
target can be made to have a higher pH than
! the bulk solution. One possible method of doing so
is to use an enzyme modified to bind to the target and then produce a basic compound. For this
system, PbSe nanoparticles bound in an agarose gel were used as the target. The enzyme used
was urease conjugated to a lead-binding peptide. When added to a solution containing urease and
the PbSe gel, the modified urease would bind to the surface of the nanoparticles and cleave
urease in that location, releasing ammonia which would lower the pH in the vicinity. The MOFDPA particle, when subsequently added, would then travel around the surface until it was
localized in the region of the PbSe. (Figure 6)
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hand-operated die press to form discs 7.6 mm in diameter and 0.5 mm thick, which were then cut
into smaller samples, approximately 2 mm by 2 mm by 0.5 mm and 2 mg mass.

1.2 Using a MOF-Peptide System as a Generator
1.2.1 Methods
The MOF used was copper benzene-1,3,5-tricarboxylate, [Cu3(C9H3O6)2]n, also known as
Basolite C-300 or HKUST-1.16 HKUST-1 is more hydrophilic than the CuJAST-1 employed in
previous work (and in the next section) and will release DPA molecules without the need for
EFTA to slowly dissolve it. Thus HKUST-1 particles remain intact and can be reused.
The rotor was cut and folded from a plastic sheet. One end of the rotor has a compartment
to hold the MOF in contact with the water while only allowing the DPA to escape in one
direction. A small permanent neodymium magnet is also glued to that end. The other end of the
rotor rotates freely around a post set in the center of a 55 mm petri dish. The dish is filled with
deionized H2O, the rotor placed on top of the surface, and the MOF/DPA sample placed in the
rotor compartment. A 1000-turn coil is attached to a signal amplifier, 15.9 Hz low-pass band
filter, and 0.15 Hz high-pass band filter. An analog-to-digital signal converter (DATAQ DL-145)
is used to record the resulting signal on a computer. Video was recorded with a digital camera.

1.2.2 Results and Discussion
After initiation of motion, the rotor rotates at an initial frequency of 1.3 Hz, gradually
diminishing to 0.67 Hz after 750 seconds. Peak power is approximately 0.1 μW. (Figure 7)
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Figure 2. a) Power generation fueled by DPA peptide–MOF motors with time. b) Expanded power generation patterns around 10 s of rotation.
c) Expanded power generation patterns around 770 s of rotation. d) Correlation between induced voltage and velocity of rotor powered by DPA–
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Figure 8: Comparison of XRD of HKUST MOF initially and after recycling 14
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In conclusion, it was shown that a MOF/peptide-driven system could be configured as a
refuellable electric generator. Power output could be increased with further optimizations to rotor
and coil design. The amount of power generated could be sufficient for powering applications
such as an sensor/transmitter; for instance radio transmitters have been designed which use less
than 0.1 nW.17

1.3 Guidance of a MOF-Peptide System to a Target
1.3.1 Methods
The MOF used was copper 1,4-benzenedicarboxylate triethylenediamine [Cu2L2ted]n (L
= 1,4-benzenedicarboxylate; ted = triethylenediamine), also known as CuJAST-1.18
To test whether a high-pH area could be used to create a trap effect for the MOF particle,
a pH gradient was created using blocks of agarose gel (with silica added to increase density and
prevent them from floating in solution) soaked in either pH 4 or pH 8 buffers to create acidic or
basic pH posts. The pH 4 solution was 1.0 mM EDTA and 1.5 mM NaOH, and the pH 8 solution
was 1.0 mM EDTA and 3.0 mM NaOH. These posts were then placed in 55 mm dishes with a
pH 5 solution of 1.0 mM EDTA and 2.0 mM NaOH. Figure 9 shows the resulting motion of a
particle, eventually slowing and stopping over the basic post. A pH indicator, phenol red, which
changes color from yellow at pH 6 or less to pink at pH 8 or more, was added in some
experiments to visualize the pH gradient.

9

protocol in Figure 1, we studied the motion of DPA-CuJAST-1
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swimming
around
solution peptide
(left),wasand
after 30
s 1017
the g/mol),
peptide-MOF
The sequence
of the Pb-binding
DHHTQQHD
(MW
and it was
motor senses the basic post and stays around the high pH area. The
ordered from Genscript. It was conjugated to the urease using the crosslinking reagent sulfosolution is adjusted as pH = 5 by mixing EDTA (1 mM) and NaOH (2
SMCC
link the N-terminus
of the peptide to cysteine
the urease asoffollows:
5 mg
mM),to yielding
the environment
for theresidue
bestofmobility
the peptideMOF motor at pH 5. The right ﬁgure shows 3D trajectory of MOF
(4.9 μmol) of peptide was dissolved in 0.2 mL of 50 mM pH 7 phosphate buffer. 10 mg of sulfomotion with time. See Movie 2 for the complete motion of directed
SMCC
was dissolved
in 1.0the
mL of
50 mM pH 7 phosphate buffer. The two solutions were
swimming
toward
target.
Figure 9: Snapshots (left, middle) and total record (right) of motion of MOF/DPA particle under influence of basic
(pH 8) post on left of dish and acidic (pH 4) post on right of dish (movie included as Figure 13) 15

combined, reacted for 30 minutes at ambient conditions, and then dialyzed overnight in a

the beginning the peptide-MOF motor was moving freely;
however, after 30 s, the motor swam more closely around the
bean urease, (96 units/mg) was dissolved in 1 mL 50 mM pH7 phosphate buffer, and the peptidebasic post. After 35 s, the motion was completed on the top of
sulfo-SMCC solution added. The solution was reacted for 2 hours at 4 °C. The solution was
base post (also see the Movie 2 in Supporting Information).
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the motor is completely stopped). In this experiment, the EDTA solution is mixed with
NaOH to control pH without acid and base posts in the container. Among pH 3.5, pH 6.2,
pH 8.1, and pH 9.9, the motor has shorter lifetime with higher pHs.!

!
°C under reflux and magnetically stirred until the PVP10K was completely dissolved. 0.16 mM
lead nitrate (Pb(NO3)2) was prepared by dissolving 0.424 g in 8 mL DEG. 0.23 mM selenous
acid (H2SeO3) was prepared by dissolving 0.237 g in 8 mL DEG. The lead nitrate and selenous
acid solutions were then simultaneously injected dropwise into the reaction flask over a period of
30 min, after which the reaction solution was kept at 240 °C for another 15 minutes before
cooling to room temperature. 100 mL of deionized water was then added to the solution, which
!
!
was then centrifuged
! to collect the quantum dots. The quantum dots were washed three times
!
with water, three times
! with ethanol, and then vacuum dried. Transmission electron microscopy
Figure S-2. TEM image of PbSe QDs. Scale bar = 200 nm. Inset shows electron

(TEM) with electron
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usedwith
to characterize
particles. (Figure 10)
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the pattern the
of PbSe.
!

!
!
! quantum dots (scale bar = 200 nm); Inset: electron diffraction pattern of QD consistent
Figure 10: TEM of PbSe
15
!
with PbSe
!
!
PbSe posts were prepared by placing 10 μL of PbSe QD solution on top of freshly
prepared agarose gels and letting them air dry for 1 hour. Gels were cut into 1 cm2 squares and
placed in 55 mm petri dishes with a pH 5 solution of 1.0 mM EDTA, 2.0 mM NaOH, and 1.0 M
urea, along with an acid gel post prepared as described above. 5 uL peptide-urease was added on

11

can
uce
ent
as
with
ing
QD
of
OF
v in

trol
T-1
and
, in

otor
idic
or is
OF
The
H (2
ideOF
cted

Letter

urease is applied because it can produce the basic environment
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Initially, the released particles typically travel in a circular motion (due to the edge of the

dish) at high speed (31.8 ± 1.2 mm/sec). The direction of travel of the particles rarely reverses,
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Figure 12: Snapshots (left, middle) and total record (right) of motion of MOF/DPA particle under influence of PbSe
post and Pb-binding urease on left of dish and acidic (pH 4) post on right of dish (movie included as figure 14) 15
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particle gradually slows and then finally stops over the basic gel post or PbSe post.
DOI: 10.1021/acs.nanolett.5b00969
Nano Lett. XXXX, XXX, XXX−XXX

Figure 13: Still from a movie showing a test with a basic gel on the left and an acidic gel on the right, showing
motion of the particle eventually slowing and stopping over basic post (See Figure 9 for visualization of particle
trajectory.)15 Full movie available online at
https://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.5b00969/suppl_file/nl5b00969_si_003.mov
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Figure 14: Still from a movie showing a test with a PbSe post on the left and an acidic post on the right, showing
motion of the particle eventually slowing and stopping over PbSe post.15 Full movie available online at
https://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.5b00969/suppl_file/nl5b00969_si_004.mov

Figure 15: Still from a movie showing a test with a PbSe post on the left and an acidic post on the right, with
indicator added to visualize pH (pink = basic), showing motion of the particle eventually slowing and stopping over
PbSe post.15 Full movie available online at:
https://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.5b00969/suppl_file/nl5b00969_si_005.mov

In conclusion, this pH-gradient-responsive MOF/peptide swimmer system demonstrates a
basic biomimetic chemotropic ability. A potential further refinement might be to improve its
chemosensory abilities by attaching an enzyme or similar molecule directly to the MOF particle
so that it could generate its own pH gradient in response to an external chemical stimulus.
Alternatively, attaching the lead-binding peptide to the MOF might enable it to collect lead ions
as it travelled over the surface as form of environmental remediation; for that application the
more durable HKUST-1 would be preferable to Cu-JAST-1 to avoid degradation of the MOF
matrix.
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Chapter 2 Methods for Preparation of Functionalized Iron Oxide Nanocages

2.1 Background
Nanometer-scale particles have attracted research attention in a wide variety of contexts
because their properties can often be considerably different from those displayed by the bulk
material.20 Nanoparticles have been proposed for a wide variety of biomedical applications, such
as drug delivery or diagnostics.21,22 Many different types of nanoparticles have been studied for
biomedical applications. Examples include liposomes and similar lipid-based systems, polymerbased particles (including micelles, dendrimers, viral capsids, solid polymers, etc.), and
inorganic particles (including iron oxides, gold, quantum dots, and silica), as well as systems
combining multiple types of particles.23 Several considerations need to be made when choosing a
nanoplatform for such applications. The first is toxicity; many materials suitable for other
applications are too toxic for medical applications. Another is bioavailability/biodistribution: can
the nanoparticle circulate long enough to reach the desired target, and how much of it winds up
in the target. Ease of manufacture, functionalization, and customization for a given application is
another consideration. For drug delivery systems, drug loading efficiency is another
consideration; a higher drug/particle mass ratio means a smaller amount of particles is needed to
achieve the desired dosage, helping to minimize toxicity concerns. The particle must also retain
the drug long enough to reach the target.
Lipid nanoparticles typically score well on toxicity. Liposome formation and
encapsulation and loading are relatively simple and processes and properties of the particles can
be varied simply by changing the lipid composition. As a result, many FDA-approved
nanoparticle products are lipid-based. They may still be subject to issues involving
biodistribution and relatively low drug loading, though.23
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Polymer nanoparticles cover a wide range of possibilities such as encapsulated structures
like micelles, highly-branched structures like dendrimers, solid particles. They may be made of
synthetic polymers like block-copolymers or biologically-derived materials like viral capsids.
Properties like surface charge and functionalization can be straightforwardly adjusted. This
allows for customization to meet many possible applications, leading to several polymer-based
nanoparticles being FDA-approved. However, toxicity and aggregation can still be issues.23
Inorganic nanoparticles are usually chosen for unique material properties (magnetic,
optical, and/or electronic) which can offer both therapeutic and diagnostic properties
(theranostic) unachievable with the other two type of particles. However, they can have more
difficulty with toxicity and solubility than purely organic nanoparticles. 23 Iron oxide
nanoparticles have been shown to be sufficiently low toxicity for in vivo use and can also have
magnetic properties which open up additional possibilities for imaging and treatment.24 So far,
iron oxide nanoparticles are the only inorganic nanoparticles to receive FDA approval, with
products based on dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs)
(Feridex/ferumoxide, Feraheme/ferumoxytol).25
Biodistribution is one of the major issues any nanoparticle for biomedical uses has to
address. The nanoparticle, if injected into the bloodstream, must circulate long enough so that
they can reach the target of interest. However, circulating nanoparticles are generally filtered out
from the bloodstream by the phagocytic cells of the reticuloendothelial system (RES) located
primarily in the liver, kidneys, and spleen.26,27 Numerous permutations of various nanoparticle
properties, such as material, size, shape, surface coating, and surface charge, have been proposed
to avoid liver uptake.27–29 An approach adopted by many studies is to simply target diseases of
the liver.30–33
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The story of Feridex and Feraheme is instructive here, as both wound up making use of
the liver’s tendency to collect nanoparticles rather than attempting to avoid it. Due to the
superparamagnetic properties of these iron oxide nanoparticles, both were originally developed
as MRI contrast agents. Feridex was approved primarily for liver MRI,34 but was later withdrawn
from the market, primarily for economic reasons.35 Instead of a MRI contrast agent, Feraheme
was approved as a treatment for iron-deficiency anemia,36 an application relying on the particles
being trapped and digested by the macrophages of the liver, kidneys, and spleen, though it does
see some off-label use as a MRI contrast agent.35,37
If the liver and the rest of the RES are evaded, the nanoparticle should ideally wind up in
the target of interest. In the case of cancer, it has been proposed that nanoparticles may
preferentially be uptaken by tumors due to the nature of tumor vascularization leading to leaky
capillary walls which can allow particles of the correct size range to pass through. This is called
the enhanced permeability and retention (EPR) effect, and is an example of so-called passive
targeting, which typically relies on some combination of the previously mentioned combination
of factors, (size, shape, charge, etc.) to draw the nanoparticle towards the target.38,39
Alternatively, nanoparticle systems may employ active targeting, typically by attaching a
biomolecule such as an antibody which has an affinity to a receptor or other surface molecule
found on the cells of interest. There are several approaches to attaching such a targeting
molecule. They can be covalently linked or attached by non-covalent interactions such as
electrostatic charge or hydrogen bonding.40
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2.1.1 Size and Shape Considerations
The size of nanoparticles is a critical factor in the behavior in biological systems. Size has
been shown to effect how long nanoparticles will circulate in the bloodstream, and how they will
be removed, how quickly they will be taken up by cells, and how they will be transported in a
cell once they are taken up.
Particles in the smallest size range (< 6 - 8 nm) will be removed from the bloodstream by
glomerular filtration in the kidneys and rapidly excreted in urine.41,42 Larger particles can get
captured by the RES, primarily in the liver, with the speed of capture and elimination tending to
increase with size, particularly for particles of size > 100 nm.29 Thus many studies have focused
on particles in the intermediate (~ 10 - 100 nm) size range. This size range is also thought to be
favorable for the EPR effect.43,44
The size of a particle will also influence how quickly it diffuses through the extracellular
matrix (ECM). In the case of EPR this would determine how far the nanoparticles could
penetrate into a solid tumor after passing through the capillary walls, thus potentially
determining their effectiveness if used as an anti-cancer treatment. Smaller particles have been
found to move farther through the ECM; for instance Cabral et al. tested 30, 50, 70, and 100 nm
nanoparticles of identical composition and found that the 30 nm particles penetrated deepest into
the tumor.43
Nanoparticles are taken up taken up into cells by endocytosis, a process in which the
cellular membrane enfolds around the particles, then buds off into an internal vesicle in the cell,
an endosome. Multiple pathways for endocytosis exists which can lead to different final
destinations (endosomes, lysosomes, etc.) in the cell, and the properties of a given nanoparticle
can influence which pathway it takes.45,46
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Once inside a cell, its cytoskeleton (composed of various protein filaments which give it
structure) becomes an important factor in the movement of nanoparticles. The cytoskeleton
effectively forms a net with holes on the order of 50 - 70 nm in diameter, and particles larger
than this will get caught in the net and move relatively slowly. Smaller particles can diffuse
rapidly, though if they have strong interactions with cellular proteins, that can slow them down.47
The shape of a nanoparticle has been proposed to have an effect both on its circulation
time and on its cellular uptake. Elongated aspect ratios have been suggested to hydrodynamically
increase circulation time,48 while at the same time increasing the probability of a particle
contacting capillary walls and subsequently being transferred out of the vasculature into a
tumor.49,50 Cellular uptake by endocytosis, in which the cellular membrane enfolds the
nanoparticle, has been shown to be influenced by curvature, with a higher curvature requiring
more energy and thus occurring slower.51
Therefore, if you want to increase circulation time and slow uptake, a high aspect ratio
may be advantageous. For drug delivery, a shape combining multiple high-aspect segments in a
hollow cage shape might provide the previously mentioned advantages while also having a high
surface area ratio for attaching cargo molecules. Black, et al, compared gold nanoparticles with
sphere, rod, disk, and cage shapes and found that cages while cages had a lower circulation time
than spheres, they had a superior ability to penetrate to the core of tumors.52
A hollow shape also has the advantage of increasing surface area to mass ratio relative to
a solid particle of the same diameter. If the nanoparticle is to be used as a drug carrier and the
cargo molecules are attached or absorbed on the surface, then maximizing surface area allows
more drug to be transported per particle, minimizing the required dosage of nanoparticle and any
potential toxicity.28
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2.1.2 Galvanic Replacement Reactions for the Generation of Hollow Nanoparticles
One method of creating hollow nanoparticles is by starting with a solid nanoparticle
template and applying an etching process that preferentially removes material from the centers of
crystal faces rather than the edges.53 One possible etching method is galvanic replacement.
Galvanic replacement is essentially a redox reaction, in which a metal ion forming part of the
template crystal is oxidized or reduced to a soluble metal ion, while a different metal ion in
solution undergoes the reverse process and takes its place in the structure.54–56
A galvanic replacement reaction will proceed when the sum of the potentials for the two
half-reactions is positive. For instance, the reduction potential of manganese (II,III) oxide
(Mn3O4) to Mn+2 is +1.82 V. The reduction potential of Fe+2 to Fe+3 is -0.77 V. The sum of the
potentials is +1.05 V, and thus it is possible to set up a galvanic replacement reaction where
manganese (II,III) oxide (Mn3O4) is replaced by iron (III) oxide (Fe2O3).57
Galvanic replacement reactions can generate hollow nanoparticles through a few
mechanisms. Both dissolution of the replaced metal atoms and deposition of the replacing metal
atoms will typically start in small, localized areas. The pinholes created by the localized
dissolution will tend to expand inwards, hollowing out the original particle, as the growth of the
clusters of the replacing metal covers the original surface of the particle and slows replacement
underneath them. Due to the different surface energies of the various surface facets of the crystal
structure, both dissolution and deposition will have different preferred faces for initiation, which
can be modified by coating of the surface with surfactants.54 Another mechanism which can
create hollow nanostructures is the Kirkendall effect. If the two metallic species have different
diffusion rates, then the faster diffusing species can diffuse outwards and away faster than it is
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replaced by the slower species, resulting in an accumulation of vacancies in the crystal lattice
which can then merge and grow into larger voids.56,58,59

2.1.3 Charge and Coating Considerations
Many nanoparticle synthesis methods result in nanoparticles coated in hydrophobic
molecules such as oleic acid, which therefore are not soluble in aqueous solutions. A common
approach to make the nanoparticles hydrophilic and biocompatible is to apply a coating of a
hydrophilic polymer in place of, or on top, of the original coating. This polymer should be stable
and non-toxic. Many polymers have been studied for coating iron oxide nanoparticles, for
instance polyethylene glycol (PEG), polysaccharides such as dextran or chitosan, and
polyethylenimine.60
To attach the coating polymer, it should have an affinity for either the particle itself or
the existing coating. In the case of iron oxide nanoparticles, one possible method of doing so is
using catechols. The catechol group has a very high affinity for iron and can thus displace oleic
acid.61–63 Therefore, a coating molecule can be used where one end has a catechol and the other
end is ionizable or charged to make the particles water-soluble. Multiple studies have been made
with various combinations of catechols, such as dopamine or dihydrocaffeic acid (Figure 16),
and polymers such as PEG.63–66
O
HO
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Figure 16: Structures of catechol and two related compounds, dopamine and DHCA, which can be used to coat iron
oxide nanoparticles
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The coatings attached to the particles also determine their surface charge. The surface
charge can have a significant effect on the biological behavior of the particle, for instance on the
speed of cellular uptake, blood circulation lifetimes, and cytotoxicity. Most reports have found
that neutral or zwitterionic particles are taken up more slowly by cells and have longer blood
circulation lifetimes than positively or negatively charged particles.67–69
Nanoparticles upon exposure to blood will acquire a protein corona, as various plasma
proteins adsorb to the particle through non-specific interactions. This process can lead to the
opsonization of the particles: their coating with molecules which signal phagocytic cells to
rapidly devour them. Minimizing the formation of the protein corona will thus increase
circulation time; coating the particle with neutral PEG (commonly with molecular weights in the
5,000 to 20,000 Dalton range) has been one popular approach to achieve this, as PEG coatings
reduce absorption of proteins.70,71

2.1.4 Crosslinking Reagents for Nanoparticle Functionalization
After coating, nanoparticles are often further functionalized with additions such as
fluorescent dyes for tracking purposes or biomolecules such as antibodies for targeting purposes.
There are several methods of conjugating compounds onto nanoparticles. One of the most used is
formation of an amide bond between a carboxyl group and an amine group using carbodiimide
chemistry. There are multiple carbodiimide reagents in use such as DCC, DIC, and EDC; this
dissertation will focus on EDC because it is water-soluble.72
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) reacts with
carboxylic acid groups to form an active O-acylisourea intermediate which readily reacts with
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amines to form amide bonds (top, Figure 17). As this intermediate hydrolyzes rapidly in the
presence of water, NHS (N-hydroxysuccinimide) is often added to the reaction to increase yield,
as it reacts with the O-acylisourea intermediate to form an NHS-ester which hydrolyzes at a
slower rate (and is thus stable enough to be isolated and stored as a dry compound) but still
reacts with amines to form an amide bond (bottom, Figure 17). It is also advantageous that any
leftover EDC or NHS intermediate which does not react with an amine will typically hydrolyze
overnight to leave behind the original carboxylate group.73 Hydrolyzed EDC/NHS can be easily
removed using one of the purification methods in Section 2.2.3.
Carboxylate

Amine

Amide product

NHS

EDC
Unstable
intermediate

Amine

Amide product

Semi-stable
intermediate

Figure 17: Formation of an amide bond between a carboxylate and an amide using EDC, with (bottom) and without
(top) the use of NHS to increase yield (byproducts not shown). The amide product is identical in both pathways.

When one of the molecules to be conjugated has only carboxylate groups, and the other
has only amines, then conjugation with EDC/NHS can be straightforwardly applied. When one
or both of them has both amines and carboxylates (e.g., a protein or peptide), then other
measures may need to be taken to avoid the proteins binding to themselves. If the other
component has only carboxylates (e.g., a nanoparticle coated with DHCA), then removing
leftover EDC/NHS after activation of the DHCA carboxylates but before addition of the protein
will prevent activation of the carboxylates on the protein and formation of amide bonds between
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two proteins. Adjusting reagent ratios can also help minimize crosslinking. Introducing a
different conjugation method that targets other reactive groups can also be useful.
One such method is the reaction of a maleimide group with a sulfhydryl to form a
thioester bond. This can be combined with amide-bond chemistry, for example in the commonly
used heterobifunctional crosslinking agent sulfo-SMCC (sulfosuccinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate, C16H17N2NaO9S, MW 436.37). Sulfo-SMCC has a
maleimide group on one end and an NHS-ester on the other end, separated by a cyclohexane
spacer (left, Figure 18).74 This combination allows the selective conjugation of two different
molecules. For instance, a molecule A containing amines but no sulfhydryls, such as a
nanoparticle coated with PEG-amine or aminodextran (R-NH2 in Figure 18), can be reacted with
the NHS-end of the sulfo-SMCC, leaving the maleimide end free (middle, Figure 18). After
removal of excess sulfo-SMCC, a molecule B with sulfhydryls (HS-R2 in Figure 18), such as an
antibody or other protein with cysteine residues, can be reacted with the maleimide end to form
an A-B conjugate. This procedure allows for the minimization of unwanted A-A and B-B
conjugates (right, Figure 18), which could lead to nanoparticles crosslinking with each other and
aggregating, even if molecule B has amines as well as sulfhydryls.
Amine

Sulfo-SMCC

Sulfahydryl

Malemide intermediate

Conjugated product

Figure 18: Conjugation of an amine-bearing molecule and a sulfahydryl-bearing molecule using the sulfo-SMCC
crosslinker (byproducts not shown)
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2.2 Nanocage Synthesis and Functionalization Methods
2.2.1 Nanocage Synthesis
Superparamagnetic iron oxide nanocages (maghemite, γ-Fe2O3) were synthesized using a
variation of the method developed by Oh, et al.57 To make the manganese oxide template
nanoparticles, 0.17 g (1 mmol) anhydrous manganese (II) acetate (Mn(CH3CO2)2), 0.67 g (0.824
mL, 2.5 mmol) oleylamine (C18H37N), and 0.14 g (0.157 mL, 0.5 mmol) oleic acid (C18H34O2)
are added to 15 mL p-xylene in a 50 mL three-necked flask. The mixture is sonicated for 10
minutes and then heated to 90 °C under reflux while being magnetically stirred. 1 mL of
deionized H2O is added, and the solution is reacted at 90 °C for 1.5 hours.
Then, to conduct the galvanic replacement reaction, 1 mL of 2.0 M iron (II) perchlorate
(Fe(ClO4)2) solution (0.51 g iron perchlorate dissolved with 0.75 ml H2O) is injected. (1 mL of
2.4 M iron perchlorate (0.61 g iron perchlorate dissolved in 0.7 mL H2O) can be used instead to
produce nanocages with more iron oxide.) After injection of iron perchlorate, the solution is
reacted at 90 °C for another 1.5 hours, then cooled to room temperature and centrifuged. This
first pellet is discarded, and the dark brown supernatant is mixed with 15 mL ethanol to
aggregate the particles. The solution is then centrifuged again, the supernatant discarded, and the
pellet resuspended in tetrahydrofuran. (Hexane or other non-polar organic solvents can be used
instead.) Figure 19 is a sample TEM image of the produced nanocages (See section 2.3.3 for
TEM details.)
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Figure 19: TEM of nanocages (scale bar = 20 nm)

2.2.2 Making Nanocages Hydrophilic
Multiple methods of replacing the oleic acid coating of the as-prepared nanocages were
tested. Z. Wei developed a method of modifying dextran with carboxyl groups, and then forming
an amide bond between the carboxyl group and the amine of dopamine using standard EDCNHS conjugation. This catechol-dextran could then be exchanged for the oleic acid on the
nanocages.75
To avoid side reactions due to the reactivity of dopamine, this required that first the
amine group of dopamine (1 in Figure 20) be protected by attaching trifluoroacetate (2), then the
catechol group protected with an acetonide using 2,2-dimethoxypropane (3), then the dopamine
group deprotected to yield dopamine(acetonide) (4),76,77 which was then reacted with
carboxymethyldextran synthesized by treatment of dextran with bromoacetic acid (5). Finally,
the acetonide was removed from the catechol group to yield dextran-dopamine (6).
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(Steps 1-3 are according to Z. Liu, et al., Tetrahedron Letters 51 (2010) 2403–2405, and B. Yan, et al., Nanoscale, 2013, 5, 5063–5066)

Figure 20: Synthesis of dextran-dopamine76,77

While that synthesis was effective, a simpler synthesis method was developed to avoid
the necessity of those multiple protection and deprotection steps. Dihydrocaffeic acid (DHCA, 3(3,4-dihydroxyphenyl)propionic acid, C9H10O4, 182.17 g/mol) is an analogue of dopamine which
has a carboxyl group instead of an amine; replacing the electron donating amine group with an
electron withdrawing carboxyl group reduces the reactivity of the aromatic ring and thus the
likelihood of cross-reactions.78 DHCA has been investigated as a coating material for iron oxide
nanoparticles.66,79 DHCA was conjugated to amino-dextran or PEG-amine using EDC-NHS
chemistry. (See Section 2.2.5 for details.)
After synthesis of dextran-catechol or PEG-catechol by either method, they were
exchanged with the oleic acid on the nanocages by combining them in DMSO with the nanocage
solution and incubating overnight before magnetic separation and resuspension in H O (Figure
2

21 a,b).
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A limitation of both procedures is the efficiency of the ligand-exchange process. DMSO
was chosen as an intermediate-polarity solvent in which both the hydrophilic polymer-catechols
and the hydrophobic oleic acid nanocages would be soluble. However, nanocages in solution in
hexane were not miscible with DMSO. Therefore, the solvent was exchanged by adding acetone
to aggregate the particles, using magnetic separation to remove the hexane, and then
resuspending in DMSO for the ligand exchange. A persistent difficulty was that the nanoparticles
would often not be fully dispersed after resuspension, leading to visible aggregation after the
ligand swap.
A procedure for avoiding this problem and reliably producing well-dispersed aqueous
nanocages was developed by changing the order of the reactions. First, a variation of a method
originally developed by Liu, et al.79 was used to replace the oleic acid with DHCA in THF, as
both oleic acid and DHCA are soluble in THF. This resulted in water-soluble, carboxylatefunctionalized, negatively-charged nanocage-DHCA (NC-DHCA), which could then have
amine-bearing molecules (such as dyes or aminopolymers like aminodextran or PEG-amine)
attached with EDC/NHS chemistry in aqueous solution (Figure 21 c,d). (See Section 2.2.6 for
details.)

28

Figure 21: Methods of replacing oleic acid on nanocages with DHCA and dextran. Synthesis of a) Dextran-DHCA
linker; b) NC-Dextran (by replacing oleic acid with dextran-DHCA (a); c) NC-DHCA (by replacing oleic acid on
nanocages with DHCA); d) NC-dextran (by conjugating NC-DHCA (c) with dextran).

As most amino-polymers have multiple amine groups which could potentially crosslink
multiple cages, resulting in larger final sizes, adjusting reagent ratios to reduce crosslinking was
necessary to minimize the size increase of the final particles.
This method can further be extended to use dopamine (top, Figure 22) instead of DHCA
(bottom, Figure 22), producing amine-functionalized, positively-charged nanocage-dopamine
(NC-dopa), which can be further functionalized using EDC/NHS chemistry to link carboxylatebearing molecules (dyes, carboxydextran, PEG-COOH, etc.)80 (See Section 2.2.7 for details.)
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Figure 22: Schematic of conversion of oleic acid coated nanoparticles to dopamine (top) or DHCA (bottom) coated
nanocages.80 Amine-conjugation on NC with carboxylic acids on polymers halts intra-NC conjugation when
polymers have multiple amine groups. If polymers have multiple carboxylic acids, DHCA could be better choice for
polymer conjugation via amine group of polymer.

2.2.3 Purification and Separation Methods of Nanocages
Multiple methods of purifying nanocage solutions and removing excess reagents and
byproducts after reactions were used in this research. The most common was magnetic
separation using the superparamagnetic properties of the particles: placing the solution next to a
magnet results in the particles accumulating on the side of the container adjacent to the magnet,
allowing unwanted liquid to be removed and replaced. The speed of this procedure is dependent
on the state of aggregation of the particles, as aggregates are more strongly attracted to the
magnet than single dispersed nanocages. As a result, completely dispersed nanocages are
separated very slowly (overnight) if at all due to comparable flow dynamics between small-sized
nanocages and solvent molecules. In other words, when a magnet is applied to oleic acid-coated
nanoparticles in THF or hexane, the solvent is entrained with the nanocages and flows to the
magnet along with the particles (see Figure 23), rendering separation ineffective.
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Figure 23: An image of nanocage solution in THF. Superparamagnetic nanocages were attracted to a magnet.

Thus, temporary aggregation of the particles (e.g., for aqueous solutions, adding
concentrated saline solution or adjusting the pH to change the surface charge of the particles; for
organic solvents, adding a more polar solvent like ethanol or acetone) is sometimes necessary to
use magnetic separation. Temporarily aggregated particles can also be collected by
centrifugation, as in the original synthesis procedure. However, a potential problem with
temporarily aggregated particles is that they are sometimes reluctant to redisperse after
separation; ultrasonication can be used to disperse them in this case.
Another frequently used method employed the size of the particles, as at >15 nm they are
larger than most molecules. This allows them to be separated from smaller molecules using a
semi-permeable membrane with pore which are too small to allow cages to pass but large enough
to allow smaller molecules. The simplest such method is dialysis: sealing the solution inside a
semipermeable membrane and suspending the package in a large amount of water or buffer so
that the unwanted small molecules diffuse out through the membrane into the surrounding water
and can be removed. Dialysis is generally quite effective, if slow. A quicker method involves the
use of devices with a semi-permeable membrane designed to speed up the separation process
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using centrifugation (e.g., Amicon Ultra centrifugal filtration devices, Millipore Sigma) which
can be used for purification, buffer exchange, or solution concentration. The solution and small
molecules are forced through the membrane under centrifugal force while the particles are
retained. However, due to the centrifugal force some particles may become stuck in the
membrane and unrecoverable, reducing yield.

2.2.4 Summary of Conjugation Schemes on Nanocages
A summary overview of potential conjugation schemes for nanocages with biomoleucles
and dyes is presented in Figure 24 below:
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Figure 24: Examples of functionalization of nanocages. a) Conversion of nanocage-oleic acid (NC-OA) to NCDHCA (See Figure 21c), followed by EDC/NHS conjugation with dye or with dextran/PEG to form NC-aminepolymer (NC-AP). See Section 2.2.8 and 2.2.9 for details. b) Conjugation of NHS-ester compound to free amine on
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NC-AP. See Section 2.2.9 for details. c) Conjugation of sulfhydryl compound (e.g., antibody) to free amine on NCAP using sulfo-SMCC crosslinker to form NC-antibody (NC-AB). See Section 2.2.10 for details. d) Conversion of
NC-OA to NC-dopamine (NC-dopa) (See Section 2.2.7 for details), followed by either conjugation with an NHSester compound, conjugation with a carboxylate-polymer using EDC/NHS, or proposed formation of a complex
between positively charged NC-Dopa and a negatively charged plasmid.

For all schemes in Figure 24, since, after the Galvanic reaction of Mn3O4 nanoparticles,
nanocages are coated by oleic acid, which is not soluble in aqueous solutions, the oleic acid
capping needs to be replaced by catechol-conjugated molecules that have a higher affinity with
iron oxide (Figure 16) before achieving goals of final conjugation structures on nanocages. This
could be accomplished by i) pre-conjugating a catechol linker with the coating molecule and then
exchanging it with oleic acid on nanocage (Sec 2.2.5 below); this was the method we developed
first, but difficulties with aggregation (as mentioned in Sec 2.2.2 above) led to the development
and adoption of ii) replacing oleic acid with a catechol-linker (e.g., usually carboxylic acid or
amine groups) and conjugating the final coating molecules with EDC/DHC or sulfo-SMCC
(below paragraphs in this section and Sections 2.2.6-2.2.8),
The EDC/NHS reaction used to attach amine-polymers such as aminodextran or PEGamine to the carboxylate groups of DHCA-coated nanocages can be generalized to attach other
molecules with amines to cages (Figure 24a). Most commonly this is used to add a fluorescent
dye so that the particles to be tracked by fluorescent microscopy.
Alternatively, after coating the nanocages with an amine-polymer such as aminodextran
or PEG-amine, amine-reactive dyes such as FITC or NHS-functionalized dyes can be attached to
exposed free amine groups of the polymers (Figure 24b). This method can also be generalized to
attach other molecules with a carboxylate group, such as biotin, by using the EDC/NHS reaction
to attach the carboxylate to an amine on the polymer.
Larger biomolecules such as antibodies can also be attached, for instance using
EDC/NHS coupling to attach the amines of lysine residues in an antibody or peptide to the
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DHCA carboxyl (using the same method as in Figure 24a (top) by replacing R1 with R3).
Alternatively, the molecules could be attached to the outside of amine-polymer-coated
nanocages, for instance by using a sulfo-SMCC linker. The linker can be added to a solution of
amine-polymer-coated nanocages, and the NHS-linkers will attach to exposed amine groups.
Then excess linker can be removed (to prevent crosslinking) and the antibody can be added. The
antibody can first be treated with a mild reducing agent such as 2-mercaptoethylamine (2-MEA)
to selectively reduce the hinge cysteine-cysteine disulfide bond, resulting in two halves with only
one free sulfhydryl each, which can then bond with the maleimide on the linker (Figure 24c).81,82
This approach reduces the potential for crosslinking between the particles, while retaining the
binding ability of the antibody.
These approaches can also be extended to dopamine-coated cages, by reversing which
component has the amine and which has the carboxylate. For instance, NHS-ester dyes can be
attached to the amine groups of NC-dopa, PEG-carboxylate and carboxyldextran can be
conjugated to NC-dopa using EDC/NHS, and so forth (Figure 24-d). The charge on the particles
could also be used to electrostatically attract molecules with the opposite charge, for example
with positively charged NC-dopa and negatively-charged DNA plasmids (Figure 24-d, bottom.)
2.2.5 Synthesis of Polymer-DHCA for Coating Nanocages
Aminodextran-DHCA (AD-DHCA) was synthesized using the following method. 100 mg
of aminodextran, 4.5 mg (25 μmol) of DHCA, 4.8 mg (25 μmol) of EDC, and 2.9 mg (25 μmol)
of NHS are dissolved in 1 mL DMSO and 1 mL pH 6 carbonate buffer and reacted overnight. 2
mL ethanol are added to condense the product, which is then collected by centrifugation. The
pellet is dissolved in deionized water, then purified with a size exclusion column (containing a
porous gel which absorbs and hinders the passage of molecules under a certain size threshold
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while allowing larger ones to flow through freely, e.g., 7K molecular weight cutoff Zeba spin
column, Thermo Fisher) and dialyzed overnight. The solution is then frozen and lyophilized.
PEG-DHCA can also be prepared with this procedure, using PEG-amine or PEG-diamine instead
of aminodextran. The molar ratio of EDC/NHS/DHCA to polymer can be adjusted to increase or
decrease the number of free amines remaining after the reaction (e.g., for attachment of dyes or
other functional groups.)

2.2.6 Replacing Oleic acid on Nanocages with DHCA (Fig. 24-a)
As-synthesized nanocages are coated with DHCA using the following method, based on
Liu (2014).79 As the nanocages would have a larger surface area per mass than the particles used
in that paper, due to their smaller size (~20 nm vs ~30 nm diameter) and being hollow rather than
solid, the primary change made was to increase the ratio of DHCA to nanoparticles from the
2.5:1 (w/w) used in the Liu paper. Several ratios from 5:1 to 30:1 were tested, and 10:1
DHCA:NC (w/w) was found to reliably result in well-dispersed, non-aggregated particles.
(Nanoparticles much smaller or larger than ~20 nm might require a different ratio; smaller
particles would have a larger surface area to mass ratio and require more DHCA to coat
completely, while larger particles would have a smaller surface area to mass ratio and require
less DHCA). It was also found that the reaction could be run under air instead of argon.
DHCA is dissolved in THF in a round-bottomed flask and nanocages dispersed in THF
are added, at a final ratio of 30 mg DHCA per 3 mg nanocage per 1 mL THF. The flask is
capped and heated to 50 °C for 3 hours with magnetic stirring. The solution is cooled to room
temperature and NaOH is added at a 1:1 molar ratio with DHCA (0.5 mL 1 M NaOH (0.5 mmol)
per 90 mg DHCA (0.5 mmol)) to ionize the DHCA and cause the particles to aggregate. The
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particles are collected by centrifugation, the supernatant (typically pink or magenta in color due
to oxidized excess DHCA) discarded, and the particles redispersed in deionized H2O and then
dialyzed overnight in deionized H2O to produce NC-DHCA as a clear brown solution with no
visible aggregation (Figure 25).

Figure 25: Solution of DHCA-coated nanocages (NC-DHCA) in water

NC-DHCA solutions in water are typically stable for extended periods of time stored at
room temperature at concentrations ≤ 2 mg/mL. (Higher concentrations tend to promote
aggregation). Sizes as determined by DLS showed small changes (± ≤ 1 nm) when retested after
9 months.

2.2.7 Replacing Oleic acid on Nanocages with Dopamine (Fig. 24-d)
A variation on a method from Liu (2015)80 was used to coat cages in dopamine. Due to
dopamine’s greater tendency to oxidize into quinones compared to DHCA, it is necessary to
exclude oxygen from this reaction. One method of doing so is to conduct the reaction in a
completely full sealed vial, as follows.
50 mg dopamine HCl (0.26 mmol) is dissolved in 1.5 mL H2O in a 27 mL glass
headspace vial. A small magnetic stirbar and 5 mg of nanocages in THF are added, and the vial
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is filled to the brim with ~25 mL THF (depending on the volume of the stirbar and nanocage
solution) and sealed using an aluminum crimp seal with PTFE/silicone septa.
The vial is then stirred for 3 hours at 50 °C. After cooling to room temperature, the seal is
carefully removed, and the solution transferred to a 50 mL centrifuge tube and then centrifuged.
(0.1 mL of 1 M HCl (0.1 mmol) can be added to aggregate the particles if they do not pellet.)
The pellet is resuspended in 2 mL deionized H2O and then dialyzed overnight in deionized H2O
to produce NC-dopa as a clear brown solution with no visible aggregation.

2.2.8 Conjugation of Polymer Coatings onto Nanocage-DHCA (Fig. 24 -a, bottom)
Nanocages coated with just DHCA can be used for in vitro experiments; however, for in
vivo use a coating such as PEG or dextran is typically required. Nanocage-DHCA are
functionalized with methods derived from Liu (2014).79 Reagent ratios were adjusted to yield the
desired degree of functionalization and DLS size while avoiding aggregation. Dextrans and
PEGs of different sizes can be used in this and the following sections; the most commonly used
had a molecular weight of 10 KDaltons, e.g. dextran, amino, 10,000, (Invitrogen #D1860) or
poly(ethylene glycol) diamine, 10,000, (Sigma-Aldrich #752460), but dextran with 40K
molecular weight and PEGs of 5K and 20K were also tried. Larger dextrans or PEGs will tend to
increase the final hydrodynamic diameter of the particles by more. PEGs had either one or two
free amines per mole, depending on whether they were monoamine or diamine. The number of
amines per mole of dextran varied depending on the manufacturer’s certificate of assay for each
lot but was typically around 4 for aminodextran 10K and 9 for aminodextran 40K. The ratios in
the method below are a 1:1 molar ratio of EDC to PEG or aminodextran for PEG/AD of
molecular weight 10,000, originally chosen with the rationale of minimizing the possibility of
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nanocages being crosslinked by multiple particles attaching to the same polymer molecule.
While this ratio might need to be adjusted for polymers of significantly different weights, the
resulting hydrodynamic sizes of the particles appear to be relatively insensitive to variations in
this ratio, as will be seen shortly. A spreadsheet, “Ratios 2” was constructed to calculate
quantities of reagents to use based on starting amount of nanocages, desired ratio between
nanocages and EDC/NHS/PEG or dextran, molecular weight of PEG or dextran, etc. (See Table
1)
To conjugate aminodextran or amino-PEG (e.g.) to NC-DHCA, using EDC/NHS
conjugation, first solutions of EDC and NHS are prepared. 40 mM EDC is prepared by
dissolving 3.8 mg (20 mmol) EDC in 0.5 mL H2O. 50 mM NHS is prepared by dissolving 2.9
mg (25 mmol) NHS in 0.5 mL H2O (as stated above, excess NHS will be removed via hydrolysis
and thus a molar excess amount of NHS can be added here to drive the reaction further towards
completion). Nanocages in aqueous solution are added to phosphate-buffered saline, pH 7, at 1 to
2 mg/mL. 2.5 μL of the EDC and NHS solutions are added per mg of nanocage (100 nmol EDC
per mg of cage). 1 mg of the aminodextran or amino-PEG is added per mg of nanocage, and the
solution is mixed well and reacted at room temperature for at least 2 hours. The conjugated
nanocages (NC-DHCA-AD or NC-DHCA-APEG) are extracted by magnetic separation and
resuspension in deionized H2O.
Increases in the ratios of both of EDC/NHS to NC and dextran to NC from the above
conditions were tested to determine the effect on particle size. Increasing the ratio of EDC had
no significant effect at the lowest dextran concentration, while increasing the ratio of dextran
increased the size at the lowest EDC concentration, indicating that dextran and not EDC is the
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limiting reagent under those conditions. The increase in size with increasing EDC ratio at a
dextran ratio of 10:1 indicates that at those conditions EDC is the limiting reagent. (Figure 26)
Based on these results the 100:1:1 = EDC : Dextran : NC (nmol : mg : mg) ratio was
adopted for coating nanocages with dextran to minimize the hydrodynamic size of the product.
This ratio was also found to work well with PEG. If increasing the size of the particles is desired,
the 1000:10:1 ratio could be used.
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Figure 26: Resulting hydrodynamic size of NC-DHCA-dextran for different reagent ratios for dextran with
molecular weight 40 kDaltons

2.2.9 Conjugation of Dyes to Nanocage-DHCA (Fig. 24-a, top)
The simplest method of labelling nanocages with fluorescent dyes is to attach aminecontaining dyes (e.g., cy5-amine, fluoresceinamine) directly to DHCA-nanocages (see Figure 24a). Dyed nanocages prepared this way are suitable for in vitro experiments involving fluorescent
and confocal microscopy. A typical conjugation protocol is as follows: 50 mM EDC and 50 mM
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NHS are prepared as in Section 2.2.8. 25 uL (0.5 μmol EDC, 0.635 μmol NHS) of each solution
is added to 1 mg of NC-DHCA in PBS. 30 nmol (typically) of dye-amine dissolved in DMSO are
added, the solution reacted 2 hours to overnight at room temperature, and then purified with
dialysis to remove excess dye and reagent. EDC/NHS is used in molar excess here, since each
dye typically has only one amine group and thus there is no danger of aggregation from
crosslinking nanoparticles with dye as there is with aminodextran or PEG diamine. However,
aggregation can still occur simply if too many dyes are bonded to the surface of the
nanoparticles, as dyes are typically relatively hydrophobic. As each dye has somewhat different
properties such as degree of hydrophobicity and brightness, the ratio of dye added may have to
be adjusted to find a balance which avoids aggregation while delivering the desired fluorescent
intensity. The spreadsheet “Ratios 2” (Table 1) was used to calculate the mass of dye needed for
a given dye ratio and dye molecular weight for any of the attachment methods in this section.
For in vivo experiments, nanocages typically must be coated with aminodextran or PEGamine (such nanocages can also be used in vitro). These nanocages can be labelled using dyes
with an NHS-ester or isothiocyanate (ITC) group (e.g., cy7.5-NHS, FITC) which can bind to free
amines exposed on the surface of the NC-DHCA-Dex or NC-DHCA-PEG (see Figure 24b). 30
nmol of dye dissolved in DMSO are added to 1 mg of NC-DHCA-Dex or -PEG in pH 8.3
carbonate or phosphate buffer (for NHS dyes) or pH 9 carbonate buffer (for ITC dyes), the
solution is reacted 2 hours to overnight at room temperature, and then excess dye is removed by
dialysis. Again, as each dye has somewhat different properties such as degree of hydrophobicity
and brightness, the ratio of dye added may be decreased to avoid aggregation or increased to
increase fluorescence.
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Alternatively, aminodextran can instead be pre-conjugated with dye and the aminodextran dye bonded to NC-DHCA (Sec. 2.2.5). Aminodextran is dissolved in 0.1 M pH 8.3
phosphate or carbonate buffer and 1 molar equivalent of dye is added. The solution is reacted at
room temperature for 2 hours to overnight. Then an equivalent volume of ethanol is added to
precipitate the dextran and the solution centrifuged. The pellet is resuspended in H2O and the
solution additionally purified by dialysis or spin column and then lyophilized and store protected
from light. The dye-labelled dextran can then be attached to NC-DHCA as per Section 2.2.8.
This method may be more efficient when planning on making multiple batches of the same
combination of nanocage, coating, and dye, as compared to the previous method, this procedure
involves one less reaction and purification step for nanocages, which can increase the final yield
of nanocage product while also saving some time, as enough dye-labeled dextran for all the
batches can be made in advance and saved. As most experiments involved producing and testing
different combinations of functional molecules/proteins for in vitro experiments one batch at a
time, this protocol was used less often, mostly for in vivo experiments which required producing
multiple batches of the same formulation of functionalized nanocages over a period of a few
weeks.

2.2.10 Conjugation of Biomolecules to Nanocages-DHCA (Fig. 24-c)
Biomolecules such as antibodies or other proteins can also be attached to nanocages, in a
few different ways (see Figure 27). They can be attached directly to NC-DHCA using EDC/NHS
to link the carboxyl groups on NC-DHCA to amines on the biomolecules; however, if the
biomolecules have multiple amine groups exposed, as is typical of proteins, this method will
attach them in a random position which may not preserve their activity.
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An alternative is to attach them to the free amine groups on aminopolymer-coated
nanocages using sulfo-SMCC linkers, after reduction of the antibody (or other protein) to expose
free cysteine residues. If dye is also to be conjugated to the nanocages, it can be added before,
along with, or after the other components, using protocols as described in the previous section.
Although PEG is used in the following methods, aminodextran could be substituted instead.
NC-HCA

IgG

Catechol

Reduced IgG

Carboxyl
Amide
Sulfahydryl

Conjugate PEG and dye

Malemide
HCA
SMCC

Direct conjuga@on
w/IgG and dye

PEG diamine

Reduced

Dye amine
Dye NHS

Figure 27: Schematic showing different methods of functionalization of NC-HCA with PEG, dye, and IgG

Multiple orders of addition of the various functionalities (antibody, dye, and/or PEG) to
NC-HCA were tested, as shown in Figure 27; antibody was always added last to reduce the
possibility of a later addition binding to and deactivating the antigen recognition region. Dye,
then antibody. Dye, then PEG, then antibody. PEG, then antibody. PEG, then dye, then antibody.
The general trend was that adding PEG first reduced particle aggregation as measured by DLS
size as seen in Figure 28. The levels of all reagents also had to be adjusted to avoid aggregation.
The primary dye tested was Cyanine 7.5 (Cy7.5, excitation 788 nm, emission 808 nm) in either
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amine or NHS-ester forms, and a dye to nanocage ratio of 15 nmol Cy7.5 per mg NC was found
to be suitable based on the DLS size and fluorescence of the product. The spreadsheet “Ratios 2”
(listed in Table 1) was used to calculate reagent ratios between nanocages, PEG, dye, antibody,
etc.
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NC-PEG

NC-PEG-Cy7.5-IgG

Figure 28: Hydrodynamic sizes after conjugation on NC-DHCA with Cy7.5 dye, PEG, and/or IgG

Antibodies (for instance, Mouse IgG Isotype Control, Invitrogen #31903) are attached to
NC-DHCA-PEG using sulfo-SMCC crosslinker by first reducing the antibody using 2mercaptoethylamine (2-MEA). 3 mg of 2-MEA are dissolved in 250 μL of PBS with 5 mM
EDTA. 50 μL of antibody solution are added to 50 μL of 2-MEA solution and incubated at 37 °C
for 90 minutes. The antibody solution is then purified using a size-exclusion column (e.g., Zeba
spin column, Thermo Scientific) and the concentration determined by measuring absorbance at
280 nm using a NanoDrop UV-Vis spectrophotometer (Thermo Fisher). (While dialysis could be
used for purification, since it takes long enough to use up a significant fraction of the time,
reduced antibodies may not remain reduced as they could oxidize back to the disulfide and then
the sulfo-SMCC scheme will not work for the conjugation). Reduced antibody remains reduced
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for at least 40 hours at 4 °C in PBS with EDTA,83 so it should be promptly used for the next step.
5.25 μL of 0.1 mg/mL sulfo-SMCC solution (12 nmol) are added per 1 mg of NC-DHCA-PEG
in PBS with 5 mM EDTA and reacted for 30 minutes at room temperature. Excess cross-linker is
then removed by either magnetic separation or centrifugal filtration, and the pellet resuspended
in PBS with 5 mM EDTA. 75 μg (1 nmol) of reduced antibody are added per 1 mg of nanocage
and the solution reacted overnight at 4 °C. The product is then purified by magnetic separation at
4 °C.
The degree of labelling with antibodies is measured by using fluorescently labelled
antibodies (such as Mouse IgG Isotype Control, Invitrogen #31505) for the conjugation to
nanocages. The fluorescence of the dye-labeled nanocage solution is measured with a plate
reader and compared to a standard curve made by measuring the fluorescence of standard
solutions of the fluorescent antibody of different concentrations. NC-DHCA-IgG had about 5.6
antibodies per cage, while NC-DHCA-PEG-IgG had about 1.2 antibodies per cage. A typical IgG
antibody is about 10-15 nm long and about 4-6 nm deep,84,85 as this method attaches halfantibodies by the hinge region in the middle of the long axis (see Figure 29), the observed
increases in hydrodynamic size by DLS in Figure 28 of ~6 nm for NC-DHCA-PEG-IgG and ~12
nm for NC-DHCA-IgG are consistent.
Half IgG
Nanocage
Nanocage
20 nm

15 nm

6 nm
NC + PEG
30 nm

Figure 29: Schematic of NC-DHCA-PEG-IgG conjugate showing relative sizes of nanocage, PEG layer, and
antibody
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2.2.11 Profiling of Drug Release from Antibody-Conjugated Nanocages
The ability of NC-DHCA-PEG-Cy7.5-IgG (NC-AB) to load and retain a drug was tested
using the chemotherapy agent doxorubicin, which has the advantage for this purpose of being
fluorescent (excitation 470 nm, emission 485 nm) and thus its concentration is easy to assay by
plate reader. Doxorubicin is loaded onto nanocages by dissolving it in DMSO at 1 mg/mL and
then adding it to samples of NC-AB in water at a mass ratio of 1:10 doxorubicin:NC-AB and
incubating overnight at 4 °C. To probe the release profile of doxorubicin from NB-AB, the
fluorescence of doxorubicin in the supernatant in the NC-AB solution was measured at
successive timepoints with the following sequence of steps. The sample was centrifuged to pellet
the NC-AB. The supernatant was removed, and the pellet resuspended in water and incubated at
4 °C until the next timepoint. The centrifugation, removal of the supernatant, and resuspension
was repeated at 4 hours, 24 hours, and 48 hours. The fluorescence of doxorubicin in the
supernatants was measured using a fluorescent plate reader and compared to a standard curve
constructed from successive dilutions of doxorubicin, and the amount released at each timepoint
summed and subtracted from the initial amount of doxorubicin added to produce Figure 30. The
average amount of the initially added doxorubicin retained at time zero was 91% ± 2% (n=6).
The average amount retained at 48 hours was 85% ± 5%. While this data would not necessarily
translate directly to behavior in vivo, it does suggest that the NC-AB can take up and retain a
significant amount of drug for long enough to potentially reach a target organ when administered
in-vivo. Accelerating the release of the drug once the nanocages have reached their target by
applying an alternating magnetic field is a possibility which will be explored in Chapter 4.
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Figure 30: Retention of doxorubicin over time in NC-AB, measured by fluorescence of doxorubicin in the
supernatant of the NC-AB solution (n=6)

2.3 Methods for Characterization of Nanocages
2.3.1 Determination of Nanocage Concentration by Iron Digestion
The iron content of nanocages in organic or aqueous solutions can be measured by HCl
digestion, using a variation of a method outlined by Rad, et al.86 This method is used for
determining concentration of solutions of nanocages coated with oleic acid before ligand
exchange. While it can also be used after ligand exchange, for nanocages in aqueous solution the
method in Sec. 2.3.2 is faster. It is possible to apply the method in Sec. 2.3.2 with organic
solutions using a separate calibration curve and organic-solvent resistant cuvettes in a normal
spectrophotometer, but it was never necessary. 5 µL of the nanocage solution to be assayed was
added to 995 µL of 5 M HCl. (For nanocage solutions in volatile organic solvents immiscible
with water, the 5 µL aliquot can instead be evaporated to dryness in a microcentrifuge tube and
then 1.0 mL of 5 M HCl added.) The solution is either sonicated for 30 minutes or heated to 70
ºC for 30 minutes, until the nanocages are completely dissolved, as indicated by the development
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of the yellow color of ferric chloride. Samples are then transferred to cuvettes and measured in a
spectrophotometer at 351 nm vs a 5 M HCl blank. If the concentration of original sample
solution is greater than approximately 3 mg/mL, the digested sample solution should be diluted
appropriately with 5 M HCl to yield an estimated concentration in the 2 to 15 μg/mL range. A
standard curve is constructed using successive dilutions of ferric chloride solutions of known
concentrations and used to calculate the mass of iron in the sample. The standard curve was then
encoded as a spreadsheet, “Nanodrop Fe digest 351 nm” (Table 1). Unless otherwise specified,
all masses of nanocages given in this dissertation are in terms of iron content.

Figure 31: Example UV/Vis spectrum of HCl-digested nanocage showing FeCl3 absorption peak at 351 nm (noise
below 300 nm is due to plastic cuvette)

2.3.2 Direct Determination of Nanocage Concentration in Aqueous Solutions
For aqueous solutions of nanocages, there is a faster and more convenient method of
assaying their iron content directly, without iron digestion, by using a NanoDrop UV/Vis
spectrophotometer (Thermo Scientific). The absorbance of a 2 µL drop of the solution is
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measured at 370 nm against an appropriate blank (water, buffer, etc.) If the original sample
concentration is greater than approximately 0.3 mg/mL, then an aliquot should be diluted with
water or buffer, as appropriate, until its concentration is < 0.3 mg/mL before measuring. The
absorbance of the sample is compared to a standard curve constructed by measuring absorbances
of serial dilutions of a nanocage solution of known concentration (as determined by the digestion
method). The standard curve was then encoded as a spreadsheet, “NC nanodrop calib 370 nm
#3” (Table 1).

Figure 32: Example spectrum of NC-DHCA in water using a Nanodrop UV/Vis Spectrophotometer

2.3.3 Determination of Size and Shape of Nanocages by TEM and DLS
Particles were imaged using transmission electron microscopy (TEM) using a JEM 2100
microscope (JEOL) at 200 kV. Sample grids were prepared by applying a 2 µL drop of a diluted
sample solution to a carbon/formvar film copper grid and allowing it to dry. Typical sample
dilutions range from 1/100 to 1/1000, depending on the initial concentration of the solution, for a
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final sample concentration of in the approximate range of 10 – 100 ug/mL. Dilutions may be
made with organic solvent (e.g. hexane) if the original solution is in organic solvent, or water, if
it is aqueous.
Hydrodynamic size measurements of particles were made using dynamic light scattering
(DLS) with a Zetasizer Nano S (Malvern Panalytical) in size-by-number mode. Typically, 1 uL
of an aqueous sample is diluted to 1 mL with water (or buffer if necessary to keep the sample
stable, i.e. antibody-conjugated nanocages), for a final concentration on the order of 1 – 10
ug/mL, and transferred to a cuvette for DLS measurement. It would also be possible to make
DLS measurements of a sample in organic solvent, using that solvent as a diluent and chemically
compatible cuvettes.

2.3.4 Measurement of Degree of Dye Conjugation
The degree of fluorescent labelling on nanocages, polymers, etc. were measured using a
plate reader (SpectraMax i3, Molecular Devices) at the appropriate excitation and emission
frequencies for the fluorophore used, with water or buffer used as a blank as necessary.
Fluorescence of the sample solutions is compared to standard curves constructed using serial
dilutions of unconjugated dye solutions of known concentration and used to calculate the amount
of dye attached to the product.
Note that nanocages have significant absorbance at wavelengths below ~450 nm (See
Figure 32), so this should be considered if measuring the fluorescence of nanocage-dye
conjugates using dyes with emission maxima ≤ 450 nm. All dyes used in this dissertation had
emission maxima > 450 nm.
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2.3.5 Measurement of Degree of Conjugation of Polymers
After conjugation reactions on aminodextran or PEG-amine (e.g., with DHCA), a
fluorescamine assay can be used to determine the degree of substitution, and number of free
amines remaining for potential further conjugations. Fluorescamine (4'-phenylspiro[2benzofuran-3,2'-furan]-1,3'-dione) binds to primary amine groups and becomes fluorescent only
when bound. 87 Serial dilutions of unconjugated aminodextran or PEG-amine are used as a
standard, and aliquots of standards and samples dissolved in PBS are combined with
fluorescamine dissolved in DMSO. Fluorescence is measured on a plate reader (SpectraMax i3,
Molecular Devices) at an excitation frequency of 390 nm and emission of 470 nm. Typical
results were from 27% to 34% free amine, or 66% to 73% substitution, for the reaction
conditions given in Section 2.2.5. These quantifications were obtained by comparing standards
of unconjugated dextran/PEG, as mentioned above.
Table 1: List of Spreadsheets Frequently Used in Chapter 2 for Nanocage Conjugation and Characterization
Calculations

Name of Sheet

Purpose

Type/Location

Ratios 2

Calculate reagent ratios for conjugation reactions
of nanocages with polymers, dyes, antibodies,
etc.
Calculate nanocage mass, volumes, number
density, etc. given measured TEM size and
assayed iron concentration
Calculate concentration of a nanocage solution,
given the absorbance of an HCl digested solution
at 351 nm and the dilution factor
Calculate concentration of a nanocage solution
given the absorbance measured at 370 nm and
the dilution factor

Google Sheets

Nanocages
Nanodrop Fe digest
351 nm
NC nanodrop calib
370 nm #3
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Google Sheets
Google Sheets
Google Sheets

Chapter 3 Nanocages as a Small-Molecule Delivery System

3.1 Background
Riluzole is a benzothiazole-derivative drug with neuroprotective effects which was
originally approved for the treatment of amyotrophic lateral sclerosis. It has been shown to block
sodium ion channels and inhibit glutamate release.88 Glutamate signaling pathways have been
shown to play a role in some cancers such as melanoma and breast cancer, leading to the
hypothesis that riluzole could block metabotropic glutamate receptors on those cancer cells,
inhibiting tumor growth.89,90 In vitro, mouse, and human trials of riluzole as chemotherapy have
shown some promising results.90–92

Figure 33: Structure of riluzole

As riluzole targets membrane receptors found on the cellular membrane, and as the shape
of nanocages was hypothesized to lead to slower cellular uptake due to the increased membrane
curvature and thus surface energy required for endocytosis, riluzole was chosen to test the
efficacy of nanocages as a drug delivery system on the hypothesis that increased time spent by
the nanocages in the vicinity of the cellular membrane would increase their delivery
effectiveness of riluzole compared to solid nanoparticles. (Figure 34)
Since under this hypothesis, solid spherical nanoparticles would be taken up by cells
more rapidly (due to the lower membrane curvature required for endocytosis) and be less
effective, oleic acid-coated iron oxide nanospheres with the same diameter as the nanocages (15
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± 2.5 nm) were purchased from Ocean Nanotech for use as a control. These nanospheres could
be functionalized in the same manner as the nanocages.

Figure 34: Nanocage carrier (left) remains around the cell membrane for longer than nanosphere carrier (right) 93

3.2 In vitro Trial of Nanocages for Riluzole Delivery
For the in vitro trial, the primary cell line used were LM7 human metastatic osteosarcoma
cells, which were chosen because it has previously been shown that riluzole inhibits growth and
induces apoptosis in these cells, and that this effect is due to riluzole targeting the mGluR5
glutamate receptor on these cells.94
For these experiments, 0.5 mg of oleic acid coated nanocages were transferred to DMSO
(at 25 mg/mL) and then 1.625 mg riluzole hydrochloride (C8H5F3N2OS·HCl) dissolved in
DMSO (at 25 mg/mL) was added and the solution placed on a rocker for one hour. Then 1.75 mg
of dextran-DHCA (prepared as previously described) in DMSO (at 50 mg/mL) was added and
the solution placed on a rocker for one hour. The particles were collected by centrifugation and
resuspended in 0.1 mL DMSO. The same procedure without the riluzole was used to prepare a
control. Using a similar procedure, controls with and without riluzole were also prepared using
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TUNEL-positive apoptotic cells (Figure 3a, red bars). In Figure
3b, percentage of apoptotic cells was calculated by dividing the
number of apoptotic cells by the number of DAPI-positive cells
for each delivery method. Strikingly, 88% of the DAPI-positive
cells were TUNEL-positive in the samples treated with the
riluzole-loaded IO-NCages. In contrast, free riluzole-treated
samples showed only 20% TUNEL positivity and only 13% of
group of DHCA has one of the highest aﬃnities toward iron
9,42,43oxide nanospheres. For confocal imaging experiments,
DAPI-positive
cells were TUNEL positive
for riluzole-loaded
iron
fluorescently-labelled
dextranoxide.
Dextran is a porous, hydrophilic, and neutral
IO-NSPs.
polymer used to cap various commercially available nano44
These results show that riluzole released from IO-NCages
particles
for medical applications,
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structure
DHCA-FITC
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μLcell
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Analysis ofCells
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solutions:
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drug is released from IO-NCages, as compared to IO-NSPs,
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Figure 2. (a) TEM image of iron oxide nanocages (IO-NCages) in (a)
low magniﬁcation and (b) high magniﬁcation. (Upper inset) An
illustration of IO-NCage; (lower inset) an electron diﬀraction of IONCages indicates the single crystalline nature of iron oxide (the facets
are assigned as (220), (311), and (400) from the inner circle).

Figure
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3. (a) Total
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oxide) 93
Controls are neat solvent of DMSO (control #1), neat IO-NCages (control #2), neat IO-NSPs (control #3), and neat riluzole (control #4). Riluzole
delivery from IO-NCages reduces the cell viability from 483 cells to 86 cells (18%) as compared to the one by neat riluzole of 39% (405 cells to 158
cells). (b) The percentages of apoptotic cells, calculated by dividing the number of apoptotic cells by the number of DAPI positive cells. Among total
LM7 cells, 88% of cells are apoptosis positive after the drug is delivered by IO-NCages, which is much higher than the riluzole delivery by IO-NSPs.

Neat nanoparticles showed minimal cell toxicity. LM7 cells treated with nanocage7359

DOI: 10.1021/acs.nanolett.6b02577
Nano Lett. 2016, 16, 7357−7363

riluzole showed markedly higher levels of apoptosis, in both relative and absolute terms, than
cells treated with neat riluzole or nanosphere-riluzole, demonstrating the improved effectiveness
of nanocages as a delivery mechanism over nanospheres or neat drug.
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Notably, this effect vanished in a separate control experiment on WI-38 human fibroblast
cells, which have fewer glutamate receptors than LM7 cells. WI-38 cells were treated with PBS,
neat nanocage, and neat riluzole as controls and NC-riluzole as the experimental condition. Neat
riluzole and NC-riluzole were both found to reduce cell proliferation by about 1/3 compared to
PBS or neat NC control, notably less effective than either were against LM7 cells. The amount of
glutamate receptors on LM7 cells and WI-38 cells was compared using immunohistochemistry
with a primary antibody for GluR1-4 (MABN832 Anti-Pan AMPA Receptor, EMD Millipore),
and WI-38 cells were found to have about 1/3 the amount of glutamate receptors as LM7 cells.
To support the hypothesis that the improved effectiveness of the nanocage delivery
system is due to their membrane targeting, LM7 cells were incubated with nanoparticles for 3
hours before fixing and confocal imaging to show cellular uptake. The resulting images show
that while nanospheres are distributed evenly throughout the cytoplasm, nanocages were found
preferentially
located
Nano
Lettersin the vicinity of the cell membrane.

Lett

4. (a)
Confocal
imagesdifferent
of osteosarcoma
incubated of
with
iron oxide nanocages
nanocages (IO-NCages)
(upper) and iron oxide sphe
Figure 36: a)Figure
Confocal
images
showing
cellularcells
distributions
fluorescent
and fluorescent
(IO-NSPs)
(bottom). Green
colorprofiles
shows the
locations
of nanoparticles
on93the sliced plane of the center of cells in the conf
nanospheres;nanoparticles
b) Corresponding
fluorescence
intensity
along
the dotted
lines in a)

imaging. Insets in red color show stained membrane for comparison. IO-NCages are localized on the membrane while IO-NSPs are internal
inside the cell after 48 h of incubation. (b) Fluorescence proﬁle of dotted lines in (a). (c) Illustrations for localizations of IO-NCages (upper)
IO-NSPs (bottom). On the basis of ζ-potential measurements, positively charged IO-NSPs are quickly internalized in cells while neutral IO-NC
remains longer on membranes so that more riluzole can be released near the location of ion channels which blocks the channel and limit glutam
binding to the receptors.
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via IO-NCage delivery due to the diminished expression of
glutamate receptors (Figure S1). Proliferation of WI-38 cells
(Figure S1) was almost three times higher than that of LM7

the drug to be released directly to ion channels, while the
NSPs are quickly internalized into the cells, resulting in
eﬀective receptor blockade (Figure 4c).

Zeta potential measurements of riluzole-loaded nanocages show their surface charge to
be neutral (0.08 ± 0.01 mV) compared to the positively-charged riluzole-loaded nanospheres (1.5
± 0.2 mV). Riluzole is positively charged, and the hollow structure of the nanocages means that
much of the surface area available for adsorbtion of riluzole is in the interior, which may allow
for improved charge screening by the dextran-DHCA coating compared to nanospheres.
In conclusion, it was shown that hollow iron oxide nanocages were an improved in vitro
delivery system for riluzole compared to solid iron oxide nanospheres. The next step was to
demonstrate that nanocages could be effective when used in vivo.

3.3 In vivo Trial of Nanocages for Riluzole Delivery
The efficacy of nanocages as an in vivo riluzole delivery mechanism was tested using a
nude mouse xenograft model using LM7 osteosarcoma cells modified to express GFP and
luciferase, enabling tumor growth to be measured by bioluminescence. The efficacy of riluzoleloaded PEG-coated iron oxide nanocages at inhibiting tumor growth was compared to that of
riluzole-loaded PEG-coated iron oxide nanospheres and neat riluzole.
Riluzole-loaded iron oxide nanoparticles (both nanocages and nanospheres) were
prepared as follows. Nanoparticles were coated with DHCA, and then conjugated with PEG.
Nanoparticle-PEG solutions (at 5 mg/mL) were combined with riluzole dissolved in deionized
water (at 2.5 mg/mL) and placed on a rocker at 4 °C for 6 hours. The solutions were then
magnetically separated to remove excess riluzole and resuspended in deionized water. By
measuring the amount of riluzole remaining in the supernatant and subtracting from the starting
amount, the amount of riluzole loaded on the cages was measured at ~ 30 molecules/cage. The
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hydrodynamic size of the riluzole-loaded particles was measured by DLS and found to be 25 nm
± 2.5 nm.
Thirty-six 5-week-old male nude mice were subcutaneously injected with 1 million LM7
cells in their right flanks. After the tumors reached ~ 200 mm3 in size on day 5, the mice were
divided into groups of 6, each of which was injected with one of the following treatments once a
day for 9 days: 1) PBS; 2) riluzole; 3) nanospheres; 4) nanospheres with riluzole; 5) nanocages;
6) nanocages with riluzole. Each injection delivered the equivalent of 75 μg/kg of nanoparticles
and/or 2.5 mg/kg of riluzole.
Tumor sizes were measured with Vernier calipers. On day 12, two mice from each group
were injected with luciferin (150 mg/kg), anesthetized with isoflurane, and imaged using an IVIS
system (Xenogen). At the end of the experiment (14 days) the mice were euthanized, and the
tumors extracted, fixed, sliced, and stained with DAPI and TUNEL assay for histological
analysis.

Figure 37: a) Average tumor volumes over time for each group of mice; b) Comparison of final tumor volumes for
the three riluzole conditions. **Result for IO-cage-riluzole is significantly different than riluzole or IO-sphereriluzole with p ≤ 0.05 (IO = iron oxide) 95
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Figure 38: In vivo bioluminescence of mice showing tumor sizes. a) Mice from control groups (PBS, nanosphere,
nanocage); b) and c) Two sets of mice in riluzole group (riluzole, nanosphere-riluzole, nanocage-riluzole), showing
decreased bioluminescence from nanocage-riluzole compared to the others. (IO = iron oxide)

Both tumor size measurements and bioluminescent imaging showed that iron oxide
nanocages with riluzole were more effective in inhibiting tumor growth than either neat riluzole
or iron oxide nanospheres with riluzole. Histology of the tumors revealed that tumors from mice
treated with iron oxide nanocages with riluzole showed higher levels of apoptotic cells than
either neat riluzole or iron oxide nanospheres with riluzole.
In conclusion, it has been demonstrated that using iron oxide nanoparticles to deliver
riluzole is more effective than injections of neat riluzole and was able to shrink tumors to barely
detectable levels. Further, as this increase in effectiveness was not seen when using iron oxide
nanospheres, it can be concluded that this increase in effectiveness is due to the shape of the
cages.
Further directions for research would include investigating the biodistribution and
pharmacokinetics of the nanocage-riluzole system. Investigating the biodistribution of how the
nanocage accumulates in various organs vs the tumor (the perennial problem of nanoparticlebased systems) could offer insight into improving the system. Study of the pharmacokinetics of
how and when riluzole is released from the nanocages in vivo and how long it persists would
provide insight into the hypothesis that increased membranal dwell time contributes to the
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effectiveness of the system; it might also reveal other contributing factors. Another area that
warrants more study would be whether treatment with the nanocage-riluzole system can inhibit
metastasis.
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Chapter 4 Application of Alternating Magnetic Fields to Nanocages

4.1 Superparamagnetism and Alternating Magnetic Fields
4.1.1 Background
One of the properties of iron oxide nanoparticles which has made them a topic of
investigation is their potential superparamagnetic properties. Magnetic behaviors of materials
arise from the innate quantum mechanical angular momentum, or spin, of electrons.
Paramagnetism arises in materials with unpaired electrons whose spins are normally
randomly aligned. When exposed to an external magnetic field, these unpaired electrons will
align parallel to the magnetic field, creating a weak magnetic attraction. When the field is
removed, the spins are randomized again by thermal fluctuations.96
By contrast, materials which are ferromagnetic or ferrimagnetic also have unpaired
electrons whose spins can align, but in these materials the spins of the unpaired electrons in a
local area, called a magnetic domain, will remain aligned with each other even in the absence of
an external field, as long as the temperature remains below a certain threshold, the Curie
temperature.96
Superparamagnetism arises in nanoparticles of certain ferromagnetic or ferrimagnetic
materials when the nanoparticles are small enough that each particle is a single magnetic domain,
with the magnetic moments of the atoms aligned. At ambient temperatures in the absence of an
external magnetic field, the magnetic moment can spontaneously oscillate over an interval
known as the Néel relaxation time. When an external magnetic field is applied, the particle
moments can align with the field in a similar but much stronger fashion than typical
paramagnetic materials.96
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Various applications have been proposed for superparamagnetic iron oxide nanoparticles.
Their attraction to an external magnet can be used to move them in a desired direction, for
instance to increase cellular uptake or to target a specific organ.97,98 Since they can be detected
via MRI, they can be used as a contrast agent (as in the case of Feraheme).37
One possibility which has been extensively investigated is to make use of the response of
SPIONs to an external alternating magnetic field (AMF). This results in the magnetic moments
of the particles also alternating; however, the changes of spin directions of the particles with
alternating frequency may not be perfectly in phase with the changes of magnetic field direction
in the AMF, with the net effect of absorbing energy from the external field and then dissipating it
as heat into the local environment. In the commonly used linear response theory (LRT) model
(so-called because it assumes that the magnetization of the particles responds linearly to the
strength of the applied field) this absorption and dissipation occurs through two mechanisms, the
Néel mechanism and Brownian mechanism.99,100
In the Néel mechanism, the magnetic moment of the nanoparticle oscillates rapidly
attempting to match the external alternating field, resulting in an internal dissipation of heat
through the crystal lattice of the particle. In the Brownian mechanism, the entire particle rotates
to try and align the magnetic moment with the external field, resulting in heat dissipation through
friction and viscosity with the surrounding medium.99
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Figure 39: Illustration of Néel and Brownian relaxation mechanisms

The relative strengths of each mechanism for a particular of conditions can be compared
by considering the relaxation time τ, the time it takes the particle to reach equilibrium with the
external magnetic field after each reversal of field polarity. The mechanism which occurs faster
(has the shorter relaxation time) will tend to occur first and thus dominate (this can also be seen
by Equation 2 as 1/τ becomes more dominant as τ becomes smaller). Thus the overall relaxation
time τ is related to the individual Néel and Brownian relaxation times (𝜏! and 𝜏" respectively)
by:99,101
# #
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The overall relaxation time is thus determined largely by the shorter of the two relaxation
times. It should be noted that 1/τ is a frequency term and thus the sum of Néel and Brownian
energy terms corresponds to the total relaxation energy term in Equation 2.
The Brownian relaxation time can be calculated with the following equation:101
𝜏" =
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Equation 3
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where η is the viscosity of the surrounding fluid, 𝑉- is the hydrodynamic volume of the
particle (the effective size of the particle when interacting with fluid), 𝑘" is the Boltzmann
constant (1.38 x 10-23 J/K), and 𝑇 is the temperature in K. Since the Brownian relaxation is
physical rotational motion, 𝜏" depending on the viscosity and the nanoparticle size makes sense.
The Néelian relaxation time can be calculated with the following equation:101
𝜏! = 𝜏. 𝑒

$%&
0
'" (
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Equation 4

Where τ is the attempt time, 𝐾 is the anisotropy constant for the particle, 𝑉1 is the
0

magnetic volume of the particle (the volume of the magnetic material of a particle, not including
non-magnetic coatings), 𝑘" is the Boltzmann constant (1.38 x 10-23 J/K), and T is the
temperature in K. The anisotropic constant 𝐾 represents the energy barrier for movement of the
magnetic moment of the particle away from the easy axis, its lowest energy state, and is
dependent on the particle’s crystal structure, shape, and surface effects; shape and surface
characteristics have a more significant effect on 𝐾 as the particle size decreases,102 corresponding
to the size regime of nanocages. The value of the attempt time τ depends primarily on the
0

material properties of the particle and, to a lesser extent, on the temperature and magnetic field
strength. Determining exact values for 𝜏. can be experimentally tricky; it is commonly assumed
to be ~ 1 nanosecond for SPIONs, though values ranging from 10-9 to 10-13 seconds have been
reported in the literature.103–105
The LRT then predicts that the energy absorbed (and dissipated) A will be:99
𝐴 = 𝜇. 𝜋𝐻2 𝜒"

Equation 5

Where 𝜇. is the vacuum magnetic permeability, 𝐻 is the magnetic field strength, and χ" is
the imaginary (out-of-phase) component of the AC magnetic susceptibility, which is:99
234#

𝜒" = 𝜒. '%(234#))

Equation 6
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where 𝜒. is the equilibrium magnetic susceptibility, and f is the frequency of the applied field in
234#

𝜒" = 𝜒. '%(234#))

Equation 6. To have

the maximum energy absorption in Eqn. 5, this function of Eqn. 6 has to be exactly out-of-phase,
χ” = χ0 / 2, corresponding to 2𝜋𝑓𝜏 = 1. Thus χ", and therefore 𝐴, are maximized when 𝑓 ~ 1/τ
(2𝜋 is necessary to convert linear frequency f to an angular frequency 𝜔). Because energy is only
absorbed by the particles when their magnetic moment lags, i.e., is out-of-phase with respect to
the changes of the external magnetic field, it is the out-of-phase component χ" of the magnetic
susceptibility which is important here. For example, when the frequency of the field f is too low
as compared to the relaxation time 𝜏, the particles can align their magnetic moments to the
direction of the field faster than the direction of the field can change, and thus the particles
remain in-phase with the field (i.e., if AMF changes much slower than flipping frequency of
magnetic moment, any change of AMF direction is immediately matched by the magnetic
moment, and thus they remain in phase) and minimal energy is absorbed. Conversely, if the
frequency is too fast compared to the relaxation time, the direction of the field changes so
quickly that the particles will be unable to catch up and will wind up back in-phase with the field
as the field direction cycles around (i.e., if the flipping frequency of magnetic moment is much
slower than the one for AMF, then magnetic moment is basically constant (e.g., both moments
start "up" and then the AMF direction changes to "down", but before slow magnetic moment can
flip to down, AMF goes up again), again reducing energy absorbed. This relation between phase
mismatch of relaxation time and energy holds for both Neel and Brownian relaxations.
Regardless of mechanism, the energy absorbed from the AMF will eventually wind up as
heat. This hyperthermia has been proposed as a direct therapeutic mechanism, for instance for
killing tumors by raising their internal temperature to the point of inducing apoptosis (typically >
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42 °C). However, bulk heating of tissue to the necessary temperatures requires a significant
amount of energy, which, given limitations on the magnetic fields that can be safely applied to
patients, in turn requires a large dosage of nanoparticles to penetrate deep within the tumor, a
goal which has been difficult to achieve by methods other than direct injection into the
tumor.24,106,107 Therefore approaches have been explored which require less delivered energy,
such as engineering nanoparticles into a thermally triggered drug delivery system, either instead
of or in combination with hyperthermia-induced apoptosis.108–110 In both cases, the heating field
could be applied only when the particles were localized at the target zone, which could be
determined by MRI. For the purposes of these hyperthermia applications, it is typically desirable
to maximize heat generation per mass of nanoparticle, or specific absorption rate (SAR), to
minimize the effective dose required. Most investigations have focused on the Néel relaxation
mechanism as the most efficient method for maximizing SAR, and have thus attempted to
optimize parameters such as particle size (typically 10-15 nm) and AMF frequency (typically on
the order of 105 Hz) accordingly.111–113
Alternatively, it has also been proposed to use the physical motion induced through the
Brownian mechanism, for instance to disrupt a liposomal membrane and release the contents, or
even to cause enough mechanical damage to cellular membranes like those of lysosomes to kill a
cell.114–116 Optimal systems for these Brownian-mechanism-based applications typically involve
larger particles and/or lower frequencies than Néel-mechanism-optimized systems.114
As can be seen from 𝜏" =

()*#
+" ,

Equation 3, increasing the viscosity of the solution will increase the relaxation time of the
Brownian mechanism 𝜏" . If this results in a change in the overall relaxation time 𝜏 at a given
frequency 𝑓 away from the optimal relaxation time (𝜏 = 1/2𝜋𝑓), the total power absorbed would
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then decrease as the motion slows down with higher viscosity of medium. Thus, if the heating of
nanoparticle solutions of increasing viscosity (e.g., by adding glycerol) is measured, and the
heating decreases as viscosity increases, this decrease can be taken as a probe of the contribution
of the Brownian mechanism to heating under those conditions.117 Experiments were carried out
to test the hypothesis that increasing viscosity should cause heating to decrease in proportion to
the contribution of the Brownian mechanism for nanocages (see Figure 47 below).

4.1.2 Methods for Application of AMF
The behavior of the particles under AMF was characterized using an induction heating
system from MSI Automation using one of the two coils shown below. Temperature
measurements were made with a Neoptix Reflex-4 fiber-optic probe thermometer.

Figure 40: Coils for AMF system. Left: 450 kHz frequency-coil, 5 turns, 5.5 cm inner diameter, 7 mm tube thickness,
60 kA/m field strength. Right: 335 kHz frequency-coil, 5 turns, 7.5 cm inner diameter, 10 mm tube thickness, 14.5
kA/m field strength

Samples, typically at 1mg/mL concentration, were suspended either in water or in
mixtures of water and glycerol in increasing amounts (25%, 50% and 75% (v/v)) to measure the
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effect of increasing viscosity. As 𝜏" depends on viscosity, if it is a significant contributor to τ for
a given set of conditions, then increasing viscosity would be expected to increase 𝜏" , τ, and thus
decrease absorbed energy.
In a typical experiment, 0.5 mL of nanocage solution was transferred to each of 4 x 1.5
mL microcentrifuge tubes in a sample holder (Figure 41) insulated with styrofoam to reduce
background heating. A temperature probe was inserted into each vial and the holder inserted into
the coil.

Temperature probes

Sample vials

Figure 41: Sample holder for 335 KHz coil. Left: Sample holder partially disassembled to show sample vial
placement. Right: Sample holder fully assembled and in position inside coil for application of AMF. Yellow lines are
fiber-optic temperature probes connected to a digital thermometer (currently only two lines are functional.)

The coil was turned on for a period of two minutes and the digital temperature display of
the thermometer was recorded using a smartphone camera, as a system to directly transfer the
temperature data onto a computer was not available. Data wat each timepoint was manually
entered into a spreadsheet “hyperthermia”, which also handled the following calculations of
curve fitting, slope calculation, normalization, heat capacity, and SAR (Table 3). The system was
allowed to cool down to ambient temperature between each experimental run. Recorded
temperatures over time were fit to a linear curve. The average slope for each experimental
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condition was normalized by subtracting the average slope for control samples with no
nanocages to obtain a heating rate in °C/sec. This was converted to a specific absorption rate
(SAR) using the mass of the nanocages and the heat capacity of the solution, calculated from the
specific heats of glycerol and water, the density of glycerol and water, and the volume used of
each. A correction factor was also applied to account for the volume contraction of the mixture.
The heat capacity C for the glycerol/water solutions was calculated as follows:
𝐶=

** 5* 6* %** 5+ 6+

Equation 7

'%7,-

Where 𝑉8 = volume of water (mL), ρw = density of water (g/mL), 𝑐8 = specific heat of water (J/g
°C), 𝑉8 = volume of glycerol (mL), ρg= density of glycerol (g/mL), 𝑐9 = specific heat of glycerol
(J/g °C), and v:; is a volume contraction factor, the percentage reduction in volume of a mixture
of glycerol and water compared to the sum of the volumes of the glycerol and water separately.
The specific absorption rate (SAR) was calculated as follows:
< >,

𝑆𝐴𝑅 = =

.

Equation 8
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Where mn = mass of nanocages used in the sample (g) and ∆T/∆t = heating rate calculated from
normalized slopes (°C/sec).
Viscosities and volume correction factors for glycerol/water mixtures were calculated
according to Volk & Kähler,118 and Cheng,119 as implemented in an calculator program available
online from Westbrook.120
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4.1.3 Characterization of Magnetic Properties of Nanocages
To determine the value of the anisotropic energy 𝐾 used in 𝜏! = 𝜏. 𝑒

/

$%&
0
'" (

Equation 4 and the equilibrium magnetic saturation
234#

𝜒. used in 𝜒" = 𝜒. '%(234#))

Equation 6, it

was necessary to characterize magnetic properties of the nanoparticles.
The DC magnetic saturation Ms (the maximum magnetization of the particles) and the
coercivity Hc (the remnant magnetization available after the field was removed) was measured at
magnetic field strengths H = -10 kOe to +10 kOe at 300 °K for nanocage batches with TEM
sizes of 23 and 28 nm. Ms can be used to approximate 𝜒. in Equation 6. Superparamagnetic
particles are expected to have low values of Hc (minimal remnant magnetization after the field is
removed).
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Figure 42: Measurement of DC magnetization of nanocages for 23 nm nanocages (left) and 28 nm nanocages
(right)
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AC susceptibility was measured using SQUID. The imaginary component χ" was
measured at three different frequencies (10 Hz, 100 Hz, 300 Hz) over a range of temperatures to
find the temperature with the peak magnetization (𝑇4 ).
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0.030

10 Hz
100 Hz
300Hz

0.015

Imaginary part of AC suscepitibility

Imaginary part of AC suscepitibility

0.020

0.010

0.005

0.000

10 Hz
100Hz
300 Hz

0.025
0.020
0.015
0.010
0.005
0.000

160

180

200

220

240

260

280

300

160

180

200

Temperature, T / K

220

240

260

280

300

Temperature, T / K

Figure 43: Measurements of the imaginary component of AC susceptibility for nanocages of 23 nm size (left) and 28
nm size (right). From these plots, Tf (23 nm, 10Hz) = 190 K, Tf (23 nm, 100Hz) = 208 K, Tf (23 nm, 300Hz) = 210 K
and Tf (28 nm, 10Hz) = 200K, Tf (28 nm, 100Hz) = 210K, Tf (28 nm, 300Hz) = 220K.

Substituting 𝜏! = 1;2𝜋𝑓 into the left side of 𝜏! = 𝜏. 𝑒
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$%&
0
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Equation 4, setting 𝑇 = 𝑇4 , taking the natural log of both sides, and
rearranging gives the following equation:
'

*

'

𝑙𝑛 4 = 𝑙𝑛 2𝜋𝜏. + 𝐾 > +&? @, A
"

Equation 9

/

Where 𝑓 is the frequency at which the AC susceptibility measurement is taken, 𝑇4 is the
temperature at which the imaginary component of the AC susceptibility is maximum, K is the
anisotropic constant, V@ is the magnetic volume of the particle, 𝑘" is the Boltzmann constant,
and 𝜏. is the attempt time. This equation and the measured data can then be used to construct
Arrhenius plots of the natural log of the inverse frequency vs the inverse of the peak temperature:

69

23nm

-2.0

-2.5

10 Hz

-3.0

-3.0

-3.5

-3.5

-4.0

In( f -1 )

In( f -1 )

-2.5

100 Hz

-4.5
-5.0
-5.5
-6.0
4.700

28nm

-2.0

10 Hz

-4.0

100 Hz

-4.5
-5.0
-5.5

300 Hz
4.800

4.900

5.000

5.100

-6.0

5.200

300 Hz
4.600

T -1 / 10-3 K -1

4.700

4.800

4.900

5.000

T -1 / 10-3 K -1

Figure 44: Arrhenius plots to determine the values of anisotropic constant 𝐾 for nanocages of sizes 23 nm (left) and
28 nm (right) from the slope of fitting. We used this 𝐾 value to calculate 𝜏! (Eqn. 4) and then these 𝜏! values were
used to plot 𝜏! versus size of nanocage in Fig. 45, as this 𝐾 value is assumed to be valid at 335 kHz for our
experimental conditions.

𝐾 was then calculated from the slopes of linearly fitted lines, taking the magnetic volume
of the nanocage particles V@ was taken to be 3/5 of that of a solid cube with the same side
lengths. This 𝐾 value was applied for calculating 𝜏! for 335 kHz (Eqn. 4), assuming that this K
is valid for 335 kHz, and then these 𝜏! values were used to plot Fig. 45 and 46. While 𝜏. values
could be calculated from the intercept, they were extremely low, ~ 10-19 to 10-24 sec, (compared
to literature values in the 10-9 to 10-13 range) and were assumed to be non-physical; this is known
to be due to interparticle interactions which Eq. 9 does not account for.121 The magnetic
properties of the nanocages are summarized in the below table.

Table 2: Magnetic properties of nanocages

Ms (emu/g)

Hc (Oe)

K (J/m3)

23 nm

39.9

6

1.36 * 104

28 nm

47.6

8

1.05 * 104
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The low measured values of Hc indicate minimal hysteresis, as expected for
superparamagnetic particles. For calculations in subsequent sections, 𝜒. was assumed to be equal
to Ms. Typical values for 𝐾 for maghemite are on the order of 104 J/m3,122,123 consistent with the
measured values for nanocages.

4.2

Comparison Between Strengths of Brownian/Néel Relaxation as Predicted by LRT

and Experimental Hyperthermia Results

The LRT predicts that at any given frequency, the power dissipation mechanism of the
nanocages depends on the size of the nanoparticles, and that for each combination of frequency
and nanoparticle, there will be an optimum size which maximizes SAR. As can be seen from
𝜏" =
𝜏. 𝑒

/

()*#

Equation 3 and 𝜏! =

+" ,

$%&
0
'" (

Equation 4, the Néel

relaxation time increases exponentially with the magnetic size of the particle, while the
Brownian relaxation time increases linearly with the hydrodynamic size. Since, according to
'

'

!

"

1𝜏=# + #

Equation 2,

the shortest

of the two times determines the dominant mechanism, below a certain size threshold (typically
~15 nm) the Néel mechanism is dominant; above that threshold the Brownian mechanism is
dominant, as can be seen in Figure 45. In this figure, log t (at 335 KHz) vs nanocage size was
plotted using the logs of Equations 1, 3, and 4:
𝜏 𝜏

𝑙𝑜𝑔(𝜏) = 𝑙𝑜𝑔 >(𝜏 𝑁+𝜏𝐵 )?
𝑁

Equation 10

𝐵
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()*#

𝑙𝑜𝑔(𝜏" ) = 𝑙𝑜𝑔 > +

",

?

Equation 11
A*&

𝑙𝑜𝑔(𝜏! ) = 𝑙𝑜𝑔(𝜏. ) + > +

",

? 𝑙𝑜𝑔(𝑒)

Equation 12

For solid spherical particles it is typically assumed that 𝑉1 is equal to 𝑉- (neglecting the size of
any coating layer); as the nanocages are hollow their volume is taken to be 3/5 of a solid particle,
resulting in: 𝑉1 =

(

𝑉
B -

( 3

= B > C 𝑑 ( ?, (d = hydrodynamic diameter of nanocage, obtained from

DLS). K is 1.36 * 104 J/m3 from Table 2 and η = the viscosity of water at 25 °C, 8.9274 * 10-4
Ns/m2. Although values for 𝜏. can be extrapolated from Figure 44, however, since this is known
to yield extrapolated values out of the rational range,121 literature values were used instead. Log
function was used in the above Eqns. 10-12 simply due to the convenience for Excel format.
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Figure 45: LRT-predicted relaxation time 𝜏 (black-dashed line) vs size of nanocage. Left: Predicted values for 𝜏2
=10-9. Right: Predicted values for 𝜏2 =10-11. These figures show the change from the Néel-dominated regime (when
the black dashed line overlays the red line, indicating that for those sizes of nanocages Néel relaxation is the
dominant factor) to the Brownian-dominated regime (when the black-dashed line overlays the green line, indicating
that for those sizes Brownian relaxation is the dominant factor) as particle size increases. For example, in the left
diagram, Néel relaxation dominates for sizes < 19 nm and Brownian dominates for sizes >21 nm. The dotted
horizontal line corresponds to 𝜏 = 1/2𝜋𝑓 for f = 335 KHz, pointing out the maximum energy absorption as magnetic
moment and AMF are completely out of phase (see page 63 for more details about correlation between phase and
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power). The intersection between the horizontal dotted line for 335 KHz and the dashed line for 𝜏 corresponds to
the size of nanoparticle the LRT predicts will maximize SAR and correspond to the location of the peaks in the
predicted curves in Error! Reference source not found..

In Figure 45, the dominance of each relaxation mode with nanocage size can be estimated
by comparison of the 1/t values of Neel and Brownian mechanisms. In this figure, as the particle
size increases, the Néel-dominated regime (when the black dashed line overlays the red line,
indicating that for those sizes of nanocages Néel relaxation is the dominant factor) transitions the
to Brownian-dominated regime (when the black-dashed line overlays the green line, indicating
that for those sizes Brownian relaxation is the dominant factor). For example, in the left diagram
of Figure 45, Néel relaxation dominates for sizes < 19 nm and Brownian dominates for sizes >
21 nm.
In Figure 46, SAR values were measured for nanocages with different hydrodynamic
sizes (as measured by DLS) in water at 335 KHz (shown by orange crossbars). The experimental
results showed a sharp peak in SAR of around 150 W/g at sizes around 21 nm. The simulation of
SAR curves from Eqns. 5 and 6 (Hc and c0 (= Ms) value is from Table 2 (23 nm), size versus t
are from Fig. 45, and f = 335kHz) fits well with experimental curves when 𝜏. value is in the
range of 10-9 to 10-11 seconds , consistent with the literature values.103–105
234#

234#

𝐴 = 𝜇. 𝜋𝐻6 2 𝜒" = 𝜇. 𝜋𝐻6 2 ∙ 𝜒. '%(234#)) = 𝜇. 𝜋𝐻6 2 ∙ 𝑀D '%(234#))
'

'

'

!

"

where # = # + #

A spreadsheet, “LRT comparison” was constructed to make the calculations using equations 2, 3,
4, 5, and 6 and generate the graph (Table 3).
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Figure 46: Comparison of the experimental SAR measurements of various sizes of nanocages with AMFs to the
theoretical results calculated from the LRT. Values for τ0 of 10-9, 10-10, and 10-11 seconds were used to demonstrate
the effect of decreasing the assumed value of τ0 on the predicted power, narrowing the peak power and moving it to
larger particles.

When nanocage size is smaller than 19 nm, the effect of increasing viscosity on power
dissipation of smaller particles should be minimal as Neel relaxation is independent of viscosity
(due to no- involvement with physical rotational motion). Above that size range, the Brownian
mechanism is dominant. When Brownian relaxation is dominant, the power dissipation via the
rotational motion should decrease very sharply with increasing viscosity as the Brownian
relaxation time 𝜏" increases.117,124 In Figure 47, when the size of nanocages was chosen to be
Brownian dominant regime, the hypothesized correlation between viscosities and SAR
measurements (blue bars) was observed. From parameters in Fig. 46, the predicted SAR (orange
bars) could be calculated, and the trend was consistent between them in Fig. 47 while overall the
drop in SAR with higher velocities was not as large as the prediction. A spreadsheet, “LRT calc”
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was constructed using Equations 2, 3, 4, 5, and 6 and data from Table 2 to make the predictions
of SAR with increasing viscosity according to the LRT. (Table 3).
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Figure 47: Measured SAR vs predicted SAR vs % glycerol for (LEFT) 22 nm particles from near the peak of the
power distribution in Figure 45, with predicted values based on data for 23 nm particles from Table 2; (RIGHT) 28
nm particles from the far right of the power distribution in Figure 45, with predicted values based on data for 28 nm
particles from Table 2 Data τ0 values of 10-10 sec were used for both predictions, based on Figure 45.

Figure 47 shows that even at the largest size of nanoparticle tested, 28 nm, which should
be very solidly in the Brownian regime and where the decrease in SAR with increasing viscosity
would be largest as predicted by the LRT, the magnitude of the observed effect is much less than
predicted, and the predicted values also differ significantly from experimental data for smaller 22
nm particles While these discrepancies may in part be due to inaccuracies in the determination of
the properties of the nanocages used to make the theoretical calculations, such as size of the
nanocages or the magnetic properties listed in Table 2, it has been noted by previous researchers
that the LRT has limitations which render it inaccurate if its simplifying assumptions, such as
linear response of particle magnetization to applied magnetic field, do not apply.100
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For instance, Tong et al., found SAR increasing for larger nanoparticles, up to 40 nm,
instead of peaking around 15 nm as predicted by the LRT. Furthermore for, the largest iron oxide
particles tested of 33 nm or 40 nm size, SAR increased when measured in 50% glycerol solution,
while 25 nm particles showed no change in SAR in 50% glycerol, again contradicting the
predictions of the LRT. In response, they developed a Modified Dynamic Hysteresis Model with
experimentally fit parameters as a better match for their data.125 A potential avenue for further
investigation is to determine if a similar approach would offer better predictive ability for the
AMF behavior of nanocages.

Table 3: List of Spreadsheets Frequently Used in Chapter 4 for Calculations Regarding Nanocages Exposed to
AMF

Name of Sheet

Purpose

Type/Location

hyperthermia

Collect and process data from AMF experiments
to calculate SAR
Calculate predicted SAR according to the LRT at
different viscosities for a particular nanocage size
Calculate predicted SAR according to the LRT
for different nanocage sizes and magnetic
properties

Microsoft Excel

LRT calc
LRT comparison

Microsoft Excel
Microsoft Excel

4.3 Nanocages as siRNA Delivery System
While a comprehensive theoretical model for nanocage behavior when exposed to
alternating magnetic fields may not exist yet, it is still possible to test such a system for drug
delivery. To test the ability to use AMF to trigger the release of drug cargo from nanocages, a
model system was chosen involving siRNA. Small interfering RNAs (siRNAs) are short
(typically ~ 20 base pairs) sequences of RNA, made to be complementary to a particular
messenger RNA (mRNA) in such a way that when introduced to the cell, they bind to the mRNA
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and mark it for cleavage by nucleases, preventing expression of the mRNA. They have been
widely deployed to silence genes and have been studied for multiple potential therapeutic
applications. These applications would require the use of a delivery system, as unmodified
siRNA will not be taken up by cells and will be rapidly cleared from the circulatory system.126
The model system used for this experiment involves B16-F10 cells modified to express
luciferase, and a siRNA (Silencer® Firefly Luciferase (GL2+ GL3), Thermo Fisher) targeted to
silence luciferase. Measurement of the light emitted when luciferin is added to the cells (using a
Pierce® Firefly Luciferase Glow Assay Kit, Thermo Fisher) can be used to detect the
effectiveness of the siRNA at silencing luciferase expression.

4.3.1

siRNA Methods
DHCA-coated nanocages were incubated overnight at a ratio equivalent to 9 x 1011

particles to 150 nmol siRNA. The degree of siRNA loading was measured by using a 30K
MWCO centrifuge filter to remove supernatant with excess siRNA. Excess siRNA was measured
using a Nanodrop spectrometer at 260 nm, and by subtraction from the original amount of
siRNA added, the loading of siRNA on the nanocages was calculated as approximately 45
siRNA per cage. Each siRNA is on the order of 2-3 nm in diameter and 7-8 nm long;127 thus a
close-packed monolayer of 45 siRNAs would take up a surface area of ~ 1000 nm2, which is
consistent with the estimated surface area of a 20 nm nanocage of ~ 2000 nm2. In one trial the
hydrodynamic diameter of the particles before siRNA addition was measured by DLS at 22.5
nm, and after siRNA addition was measured at 24.6 nm, a difference consistent with the addition
of an siRNA monolayer to the particle.
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For the experimental conditions, 9 x 1011 NC-siRNA particles suspended in media were
applied to B16-F10-luciferase cells grown in 24-well plates. As controls, equivalent amounts of
media, siRNA in media, or nanocages in media were used. Plates were incubated for 24 hours
before measurement as per the protocol in the assay kit. Experimental plates were exposed to 5
minutes of AMF at 335 KHz at the 18-hour timepoint.

4.3.2 siRNA results and discussions
Application of AMF to cells treated with NC-siRNA produced a reduction in luciferase
expression of 51%. None of the control treatments produced any significant inhibition of
luciferase expression, and NC-siRNA did not inhibit luciferase expression in the absence of
AMF application. (Figure 48) This demonstrates that the application of AMF is necessary for the
release of the siRNA from the nanocages inside the cells where they can silence gene expression.
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Figure 48: Luciferase expression of cells, normalized to control. a) Without AMF treatment, no change is observed
for any condition; b) with AMF treatment, nanocage-siRNA is significantly lower than controls **p <0.05 (IO =
iron oxide)
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Furthermore, suppression of luciferase expression was only observed when nanocages in
a 20-22 nm size range corresponding to the peak SAR observed in the data in Error! Reference
source not found. were used, while 15 nm cages, which would be projected to have a low SAR,
generated no significant suppression when AMF was applied, as seen in Figure 49.
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Figure 49: Comparison of results of AMF application to 15 nm and 20 nm nanocages, either neat, loaded with a
control siRNA, or loaded with the experimental siRNA. Results normalized to control (media). (IO = iron oxide)

Although the level of reduction in expression is smaller than transfection agents such as
lipofectamine commonly used for in vitro experiments (as reported in the manufacturer’s
specification sheet for Silencer® Firefly Luciferase (GL2+ GL3) siRNA128), those carriers can
not necessarily be used in vivo, and a nanocage-based system has already been demonstrated in
vivo with riluzole. The efficiency of this system could potentially be improved with
optimizations in nanocage properties such as coating, and the frequency, timing, and duration of
AMF. Further research in this area could include more detailed characterization of the
mechanisms of cellular uptake and AMF-triggered release, which might also offer insight for
potential improvements in the effectiveness of the system. The system should also be tested
against a specific disease model with a proposed therapeutic siRNA.
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4.4 Conclusion

This dissertation has outlined how superparamagnetic iron oxide nanocages can be used
as a drug delivery system, and shown how they meet several of the basic criteria for such a
system. Neat nanocages have been found to show minimal cell toxicity in vitro. It has been
demonstrated that nanocages can be coated and functionalized to make them sufficiently watersoluble and biocompatible and that they can load sufficient amounts of a drug to have a
therapeutic effect and retain that drug for long enough to reach a target of interest. Evidence
shows the hollow shape of the particles offers a significant advantage over solid spherical iron
oxide nanoparticles. Finally, the ability to trigger release of a cargo by application of an external
alternating magnetic field offers a capability not found in purely organic nanoparticles.
Much work remains to be done to establish the utility of this system for biomedical
applications. Effectiveness of magnetically-triggered release of siRNA needs to be demonstrated
in vivo. Biodistribution is the critical question for all biomedical nanoparticle systems, and a
detailed study of the biodistribution of nanocages in vivo remains to be done. Other possibilities
for investigation include varying the parameters of the nanocage synthesis (reagent ratios,
different carboxylic acids, temperature, time, etc.) to produce different sizes and shapes,
optimizing the parameters of the alternating magnetic field (frequency, power, duration, etc.),
and other variations of coating and functionalization (for instance, could the nanoparticles be
combined with a lipid coating to produce a system that had the advantages of both lipid and
inorganic nanoparticles.)
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Table 4: List of Abbreviations
2-MEA
2-mercaptoethylamine
AD
aminodextran
AMF
alternating magnetic field
APEG
amine-PEG
CuJAST-1
a copper-based MOF
Dex
dextran
DHCA
dihydrocaffeic acid
DLS
dynamic light scattering
DMSO
dimethylsulfoxide
Dopa
dopamine
DPA
diphenylalanine
EDC
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
EDTA
ethylenediaminetetraacetic acid
EPR
enhanced permeability and retention
FITC
fluorescein isothiocyanate
HFP
1,1,1,3,3,3-hexafluoro-2-propanol
HKUST-1
a copper-based MOF
IgG
immunoglobulin G antibody
IO
iron oxide
LRT
linear response theory
MOF
metal-organic framework
NC
nanocage
NC-AB
nanocage-antibody
NC-AP
nanocage-aminopolymer
NC-CP
nanocage-carboxypolymer
NC-DHCA
nanocage-DHCA
NC-dopa
nanocage-dopamine
NC-OA
nanocage-oleic acid
NHS
N-hydroxysuccinimide
PBS
phosphate-buffered saline
PbSe QD
lead selenide quantum dots
PEG
polyethylene glycol
SAR
specific absorption rate
siRNA
short interfering RNA
SPION
superparamagnetic iron oxide nanoparticles
SQUID
superconducting quantum interference device
sulfo-SMCC sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
TEM
transmission electron microscopy
THF
tetrahydrofuran
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